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Abstract 
The synthesis of well-defined oligosaccharides is crucial for the establishment of 
structure-activity relationships for specific sequences of heparin, contributing to the 
understanding of the biological role of this polysaccharide. It is highly convenient that 
the synthetic oligosaccharides contain an orthogonal functional group that allows 
selective conjugation of the probes and expands their use as chemical tools in 
glycobiology. We present here the synthesis of a series of amine-functionalized heparin 
oligosaccharides using a n+2 modular approach. The conditions of the glycosylation 
reactions were carefully optimized to produce efficiently the desired synthetic 
intermediates with an N-benzyloxycarbonyl-protected aminoethyl spacer at the reducing 
end. The use of microwave heating greatly facilitates O- and N-sulfation steps, avoiding 
experimental problems associated with these reactions. The synthesized 
oligosaccharides were immobilized in 384-well microtiter plates and successfully 
probed with a heparin-binding protein, the basic fibroblast growth factor FGF-2. The 
use of hexadecyltrimethylammonium bromide minimized the amount of sugar required 
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for attachment to the solid support. Using this approach we quantified heparin-protein 
interactions, and surface dissociation constants for the synthetic heparin derivatives 
were determined.      
Introduction 
Glycosaminoglycans (GAGs) are natural, linear polysaccharides that in general present 
a high level of sulfation. This family of molecules includes heparin, heparan sulfate, and 
chondroitin sulfate, among others. GAGs are biosynthesized in the Golgi apparatus of 
eukaryotic cells through the sequential action of a series of enzymes. This natural 
process results in GAG chains with a high level of structural diversity. The 
heterogeneity of GAG polysaccharides enables their binding to a wide range of 
proteins.1-5 As a consequence of these interactions, GAGs influence many biological 
processes such as inflammation, angiogenesis and blood coagulation.6 However, the 
GAG structural requirements for binding and mediating biological activity have been 
only established for a few cases, the most studied example being the interaction of 
antithrombin with heparin.7 In many other cases, the encoded information contained in 
specific GAG sequences is still poorly understood. This fact can be explained by the 
difficulties to obtain well-defined, homogeneous GAG oligosaccharides from natural 
sources, due to the structural complexity of these molecules. 
In this context, chemical synthesis appears as an alternative, powerful tool to access 
well-defined GAG oligosaccharides8, 9 for the determination of structure–activity 
relationships and the correlation of specific sequences and sulfation patterns with 
protein binding and biological activity.10, 11 Furthermore, chemical synthesis can 
provide unnatural GAG sequences and analogues, as potential tools to modulate GAG-
protein interactions.  
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It is highly desirable that synthesized structures contain an orthogonal functional group, 
with unique reactivity, for further selective conjugation of the probes.12 The 
incorporation of such a group, usually at the reducing end of the oligosaccharide, opens 
the way for a wide variety of valuable experiments in glycobiology. For example, 
orthogonally functionalized sugars can be selectively immobilized on glass surfaces to 
create carbohydrate microarrays for the high-throughput screening of interactions,13, 14 
or selectively conjugated to multivalent scaffolds to generate heparin/GAG mimetics.15-
17 The protecting group that masks this orthogonal functionality should be compatible 
with the complex protecting-group strategy required for the synthesis of heparin 
oligosaccharides.  
Since the pioneering synthesis of the antithrombim III binding heparin 
pentasaccharide,18 several synthetic approaches for heparin have been described,19-31 
including polymer-supported strategies,32-35 preactivation-based one-pot synthesis,36 and 
reactivity-based one-pot synthesis.37 Despite all these significant advances in the field, 
the synthesis of these molecules is still a challenging task. Various difficulties are 
associated with these syntheses due to the complex structure of heparin and the great 
diversity of native sequences. A careful design of an appropriate set of protecting 
groups is required for the introduction of sulfate groups on selected hydroxyl and amino 
functions and for the stereoselective construction of glycosidic bonds. These protecting 
groups can have a profound effect on the efficiency of glycosylation reactions that 
sometimes is not easily predictable. On the other hand, deprotection/sulfation steps may 
require more effort and time than the assembly of the protected intermediates. These 
final steps, particularly sulfation reactions, on valuable and elaborated compounds, 
often lead to a significant decrease in isolated overall yield.  
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We report here the preparation of a series of heparin oligosaccharides (one di-, one 
tetra- and two hexamers) that contain the GlcNSO3(6-OSO3)-IdoA(2-OSO3) repeating 
unit of the major sequence of heparin. An aminoethyl spacer was placed at the reducing 
end of the structures. A careful optimization of the reaction conditions was necessary 
for the efficient glycosylation of building blocks containing an N-benzyloxycarbonyl-
protected amino spacer. The use of microwave irradiation facilitated O- and N-sulfation 
steps, reducing reaction times and increasing isolated yields.38 The reported 
experimental protocol adds valuable knowledge to the existing data on heparin-like 
oligosaccharide synthesis. Furthermore, the synthesized oligosaccharides were 
immobilized in appropriate microtiter plates by using the anomeric amino group. The 
resulting heparin arrays were employed to measure, qualitative- and quantitatively, 
sugar-protein interactions. We demonstrated the utility of this system by studying the 
carbohydrate affinity of a well-characterized heparin-binding protein, the basic 
fibroblast growth factor FGF-2 that is implicated in angiogenesis, cell growth and 
differentiation. 
Results and discussion 
Synthesis of amine-functionalized heparin oligosaccharides 
For the synthesis of these orthogonally functionalized oligosaccharides, we followed a 
stereoselective n+2 modular approach that utilized disaccharide 4 as key building block 
(Scheme 1). 4 was prepared by glycosylation of trichloroacetimidate 126 and diol 239 
followed by pivaloylation at position 2, desilylation and anomeric activation, according 
to the synthetic strategy developed by Martín-Lomas and co-workers.40 Interestingly, 
lactone 5 was systematically detected in the desilylation and trichloroacetimidation 
reactions.41 This side product resulted from intramolecular transesterification of the 
methyl ester group with the free anomeric hydroxyl group and could be totally removed 
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by silica gel chromatography at a later stage. Then, we introduced a protected 
aminoethyl spacer at the anomeric position. The choice of the amino protecting group is 
a crucial point of the synthetic scheme. The yields of glycosylation reactions are 
significantly lower when using benzyloxycarbonyl amino linkers as reported by 
Seeberger and co-workers20 and recently indicated by Boons and co-workers.21 An 
alternative N-(benzyl)benzyloxycarbonyl-amino linker has been successfully considered 
to avoid the deactivating effect of the –NH group. However, in preliminary experiments 
on a model monosaccharide, we found that the use of N-(benzyl)benzyloxycarbonyl 
amino spacer did not provide the target compound (Scheme 2). Final hydrogenolysis 
over Pd(OH)2 proceeded sluggishly and gave a complex mixture of compounds. 
Interestingly, Boons and co-workers reported a similar difficulty in the one-step 
hydrogenation of a heparin hexasaccharide containing benzyl ethers and a N-
(benzyl)benzyloxycarbamate, although they could solve this problem by using a two-
step procedure involving hydrogenation over Pd/C and then over Pd(OH)2.
21  
On the other hand, hydrogenolysis of monosaccharide 6 gave cleanly the fully 
deprotected compound 7. For this reason, we decided to employ N-benzyloxycarbonyl 
aminoethanol to protect the reducing end of our synthetic structures. Thus, 4 was 
efficiently transformed into acceptor 9 (Scheme 1). 
We then investigated the glycosylation between 4 and 9 under standard conditions 
(table 1, entry 1) using catalytic TMSOTf as promoter at 0ºC, but no target 
tetrasaccharide was isolated. The acceptor 9 and the hydrolized donor 3 were recovered 
from the reaction mixture. We found that addition of further quantities of promoter (up 
to 30 mol % with respect to the donor) was necessary to obtain tetrasaccharide 10 in 
good yield (table 1, entry 4). Glycal 11 was detected as side product in the experiments 
carried out with large amounts of TMSOTf (table 1, entries 2-4). Treatment of 
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tetrasaccharide 10 with hydrazine monohydrate in a pyridine/acetic acid solution 
followed by coupling with 4 afforded hexasaccharide 13 that was subsequently 
delevulinated (→14, Scheme 3). 
With the oligosaccharides 9, 12 and 14 at hand, we initially planned the benzylation 
reaction of OH-4 under neutral conditions in order to introduce the required permanent 
protecting group at this position of the non-reducing end. Treatment of 9 with BnBr and 
silver oxide in DMF gave the fully protected disaccharide 15 although in low 25 % 
yield (Scheme 4).42 Starting material and two side products, one resulting from the N-
benzylation of the carbamate linker and a second one derived from H-5 iduronic acid 
elimination reaction43 with concomitant cleavage of the GlcN-IdoA glycosidic bond, 
were detected in the reaction mixture by mass spectrometry and NMR. Attempts of 
consuming 9 with longer reaction times resulted in an increase of byproduct formation 
and lower yields of target 15. Therefore, an alternative approach was considered to 
install a permanent benzyl group at position 4 of the non-reducing end of the 
oligosaccharides involving glycosydation with capped disaccharide 18 (Scheme 5). 
Coupling of monosaccharide 1619, 26 and diol 2, followed by pivaloylation at position 2, 
desilylation and trichloroacetimidate activation gave 18. Then, glycosylation of 9 with 
18 afforded tetrasaccharide 19 in moderate yield (Scheme 5). A considerable amount 
(45%) of unreacted starting material was recovered from the reaction mixture. 
Surprisingly, analogous coupling between 12 and 18 failed to provide the corresponding 
hexasaccharide 20 under the reaction conditions previously optimized for the 
preparation of similar oligosaccharides (Table 2, entry 1). This reaction was also 
unsuccessful at room temperature, using the inverse procedure44 and lowering the 
amount of TMSOTf (Table 2, entries 2-4). In all cases, the acceptor was partly 
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recovered and only traces of the desired hexasaccharide were detected in the crude 
mixtures by mass spectrometry.  
Poor yields of glycosylations involving NH-benzyloxycarbonyl containing sugars can 
be associated with those obtained with N-acetylglucosamine derivatives. 
Bonnaffé and co-workers reported the failure of a glycosylation between a 2-
azidoglucose trichloroacetimidate disaccharide donor and a range of disaccharide 
acceptors containing an N-acetyl group.45 They demonstrated that the presence of the 
NHAc group, even at a position remote from the reactive OH acceptor, inhibits the 
coupling. The low reactivity of the 4-hydroxy group of N-acetylglucosamine acceptors 
and the poor yields associated with glycosylations at this position have long been 
known. Several explanations have been proposed for this general trend in preparative 
carbohydrate chemistry. It has been demonstrated the participation of the NHAc group 
in intra- and intermolecular hydrogen bonds that decrease the reactivity of the OH 
group.46 Alternatively, poor yields of couplings of N-acetyl containing carbohydrates 
also result from the formation of stable glycosyl imidate side products.47 These 
intermediates, proposed as the kinetic products of a glycosylation reaction, derive from 
the nucleophilic attack of the oxygen of the NHAc group to the oxocarbenium cation. 
Auzanneau and co-workers reported successful glycosylations at OH-4 of N-
acetylglucosamine using an excess (2 equiv.) of a mild Lewis acid such as BF3·Et2O at 
elevated temperatures.48-50 They hypothesized that 1 equiv. of BF3·Et2O interacts 
noncovalently with the nucleophilic N-acetyl group and the second one promotes 
coupling. We decided to employ these conditions for the coupling between 12 and 18. 
We envisioned that the excess of BF3·Et2O would reduce the nucleophilicity of the N-
benzyloxycarbonyl group. Gratifyingly, coupling between 12 and 18 with 1.5 equiv. of 
BF3·Et2O at room temperature gave the target hexasaccharide 20 in acceptable yield 
 8 
(Table 2, entry 5). A larger excess of donor or the application of the inverse procedure44 
did not significantly improve the yield (Table 2, entries 6-7). As long as sugar 
derivatives withstand treatment with multiple equivalents of Lewis acid, these 
conditions seem an attractive and practical alternative to couple unreactive building 
blocks containing N-benzyloxycarbonyl groups.  
After preparing the fully protected oligosaccharides 15, 19 and 20, we carried out the 
deprotection and sulfation steps to produce the final amine-terminated probes. The use 
of microwave irradiation greatly facilitated O-sulfations, avoiding experimental 
problems associated with this chemical transformation such as long reaction times and 
poor isolated yields.38 
Treatment of 15 with lithium hydroperoxide and then NaOH hydrolised acyl and methyl 
ester groups. Then, O-sulfation using SO3·Me3N in DMF at 100ºC under microwave 
heating gave the corresponding di-O-sulfated disaccharide in excellent yield. Reduction 
of the azido group using Staudinger conditions followed by N-sulfation using SO3·Py, 
and hydrogenolysis to remove benzyl and carbamate groups yielded the desired 
disaccharide 21 in excellent  45 % isolated yield from 15 (Scheme 6), averaging 85% 
yield per step.  
Starting from tetrasaccharide 19, saponification followed by microwave-assisted O-
sulfation, Staudinger reduction, N-sulfation and hydrogenolysis afforded tetrasaccharide 
22 in 36% yield over five steps (Scheme 6). We also performed the deprotection and 
sulfation of hexasaccharide 14 to obtain a non-natural heparin-like oligosaccharide that 
contains an additional O-sulfate group at position 4 of the non-reducing terminus, not 
presented in heparin. The removal of methoxycarbonyl and acyl groups was performed 
on 14 with lithium hydroperoxide and then NaOH (Scheme 7). The resulting saponified 
hexasaccharide was O-sulfated by treatment with SO3·Me3N complex under microwave 
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irradiation and submitted to Staudinger reduction. At this point, conventional N-
sulfation with SO3·Py complex in a mixture Et3N/pyridine at room temperature afforded 
a complex mixture of partially sulfated hexasaccharides. Fortunately, the same reaction 
proceeded smoothly with microwave heating, using SO3·Me3N in DMF/Et3N at 60ºC, to 
afford the N-sulfated intermediate in excellent yield after simple gel filtration. To the 
best of our knowledge, this is the first example of microwave-assisted sulfation of an 
amine group. These results highlight the potential of microwaves to overcome practical 
problems presented during sulfation steps. Final hydrogenation afforded deprotected 
hexasaccharide 23. Similarly, the deprotection/sulfation sequence was carried out on 
fully protected 20 to give target hexasaccharide 24 (Scheme 7).  
Binding studies in microtiter plates 
The amine-functionalized heparin-like oligosaccharides 21-24 were immobilized in 
Nunc Immobilizer AminoTM microtiter plates. Monosaccharide 7 was used as negative 
control. We employed 384-well plates to minimize the volume of sugar solutions 
required for immobilization. Oligosaccharides were dissolved in sodium bicarbonate 
buffer (50 mM, pH 9.6) and incubated overnight at room temperature in the microtiter 
plate wells. During optimization of this protocol it was found that the addition of 
hexadecyltrimethylammonium bromide in the immobilization buffer, at 100-fold higher 
concentration than the carbohydrate, greatly reduced the sugar concentration required 
for efficient attachment. The use of this ammonium salt has been previously reported to 
improve the efficiency of the attachment of heparin oligosaccharides to SPR gold 
chips.15, 51 We hypothesized that electrostatic repulsion between highly sulfated 
oligosaccharides that could hamper their coupling to a solid support is reduced in the 
presence of positively charged micelles, facilitating the immobilization of these 
compounds in the wells. In this way, as low as 10 µM concentration of sugar in 
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immobilization buffer containing 1 mM of hexadecyltrimethylammonium bromide 
resulted in adequate attachment to study binding events in the wells.  
After immobilization and subsequent quenching with ethanolamine, the binding of the 
attached compounds to a model heparin-binding protein, FGF-2, was studied. The 
binding assay involved incubation with the protein, followed by incubation with anti- 
FGF polyclonal and fluorescently labelled secondary antibodies. Bound protein was 
detected by using a standard fluorescence microplate reader. No binding of the 
antibodies to wells without FGF-2 was observed. Fluorescence signals at hexa- and 
tetrasaccharide positions (Figure 1) were observed. FGF-2 bound to disaccharide 21 
with the lowest affinity while no interaction was detected for disulfated monosaccharide 
7. These results are in good agreement with the minimal structural requirements of 
GAGs to bind FGF-2.20, 52-54 Interestingly, the short length of the C-2 amino spacer did 
not negatively influence sugar recognition.  
Figure 1 shows a one-step qualitative analysis using only one protein concentration. 
This experiment gives information to differentiate compounds that interact strongly (22, 
23, 24), weakly (21) or not at all (7) with FGF-2. However, classification of relative 
binding strengths of hexasaccharides 23 and 24 and tetrasaccharide 22 from this 
experiment can be inaccurate. Ranking of relative binding affinities requires the 
quantification of the interactions by using different protein concentrations.55, 56 Thus, 
oligosaccharides 22, 23 and 24 were incubated with 9 concentrations of FGF-2, ranging 
from 581 to 3 nM. For each sugar, average fluorescence intensities of five replicate 
wells were plotted against protein concentration (Figure 2). Assuming that the system 
reached equilibrium during incubation, the curves were analyzed as Langmuir isotherms 
to determine surface dissociation constants (KD, surf).
55 The best fit was obtained with a 
one-binding site model. All the KD, surf values were similar and indicated 
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oligosaccharide binding to FGF-2 in the nanomolar range. The KD, surf values for 
hexasaccharides 24 and 23 were close, 32 ± 4 and 44 ± 7 nM respectively, suggesting 
that the presence of a non natural sulfate group at position 4 of the non reducing end of 
23 did not significantly affect binding. A KD, surf value of 68 ± 11 nM was determined 
for 22, indicating a slight reduction in affinity compared to the hexasaccharides. These 
values were consistent with previous measurements of heparin-FGF2 binding 
affinities.57 These results show that the apparent binding strength of heparin-protein 
interactions can be quantitatively analyzed by this method with small amounts of 
carbohydrate and protein and using standard microplate equipment.             
Conclusions 
In summary, we have reported several practical improvements that facilitate the 
production of amine-functionalized heparin-like oligosaccharides. We have 
demonstrated that the difficulties encountered in glycosylations involving N-
benzyloxycarbonyl containing building blocks can be overcome by the use of an excess 
of BF3·Et2O. These couplings are often associated with poor yields due to the 
nucleophilicity of the NH group. We have shown that the application of these reaction 
conditions can solve this problem as long as donor and acceptor are stable under these 
harsh conditions. On the other hand, microwave heating increased the yield and 
efficiency of O- and N-sulfations. The use of microwave irradiation avoided some 
problems related to the complete sulfation of oligosaccharides containing multiple OH 
and NH2 groups. Moreover, we have developed an approach to study interactions 
between these synthetic oligosaccharides and proteins in microtiter plates. Highly 
negatively charged sugars were efficiently attached to the solid surface with the help of 
positively charged hexadecyltrimethylammonium bromide. The binding of the 
immobilized oligosaccharides to FGF-2 was analized qualitative- and quantitatively by 
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using standard microplate equipment, with minimal consumption of sugar (0.2 
nmol/well) and protein (pmol/well). The presented approach provides useful 
information for the preparation of heparin oligosaccharides and the evaluation of their 
interactions with proteins that are crucial aspects to improve our understanding of the 
biological role of heparin at the molecular level.    
 
 
 
 
Scheme 1. Synthesis of disaccharide building blocks. 
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Scheme 2. Previous experiments with glucosamine monosaccharides.  
 
 
 
Table 1. Reaction conditions for the glycosylation between 4 and 9 
 
Entry 
Ratio 4/9 
(equiv.) 
TMSOTf 
(equiv.) 
T (ºC) 
Recovered 9 
(%) 
Isolated 
yield (%) 
1 1.3/1 0.05 0 93 - 
2 1.3/1 0.26 25 43 27 
3 1.3/1 0.26 0 50 25 
4 1.5/1 0.45 0 23 74 
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Scheme 3. Synthesis of hexasaccharide intermediate 14. 
 
 
Scheme 4. Benzylation of disaccharide 9. 
 
 
 
Scheme 5. Synthesis of tetrasaccharide derivative 19. 
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Table 2. Reaction conditions for the glycosylation between 18 and 12 
 
Entry 
Ratio 18/12 
(equiv.) 
Promoter/ 
equiv. 
T (ºC) 
Recovered 12 
(%) 
Isolated 
yield (%) 
1 1.5/1 TMSOTf/0.45 0 71 - 
2 1.5/1 TMSOTf/0.45 25 99 - 
3 1.5/1 TMSOTf/0.15 0 99 -a 
4 1.5/1 TMSOTf/0.45 25 67 -a 
5 1.6/1 BF3·Et2O/1.5 25 27 52 
6 2.5/1 BF3·Et2O/1.75 25 39 61 
7 1.6/1 BF3·Et2O/1.5 25 60 19
a 
a Inverse procedure 
 
 
 
Scheme 6. Synthesis of disaccharide 21 and tetrasaccharide 22. Reaction conditions: a) 
LiOH, H2O2, THF; NaOH, MeOH; b) SO3·Me3N, DMF, 100ºC, MW; c) Me3P, THF, 
NaOH; d) SO3·Py, Py, Et3N; e) H2, Pd(OH)2, H2O/MeOH, 21, 45%; 22, 36%, five steps. 
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Scheme 7. Synthesis of hexasaccharides 23 and 24. Reaction conditions: a) LiOH, 
H2O2, THF; NaOH, MeOH; b) SO3·Me3N, DMF, 100ºC, MW; c) Me3P, THF, NaOH; 
d) SO3·Me3N, DMF, Et3N, 60ºC, MW; e) H2, Pd(OH)2, H2O/MeOH, 23, 30%; 24, 13%, 
five steps. 
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Figure 1. Binding of synthetic heparin-like oligosaccharides to FGF-2. Sugar-coated 
wells were incubated with 291 nM protein. For each oligosaccharide, fluorescence 
signals are the average of five replicate wells and the error bars show the standard 
deviations for these measurements. 
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Figure 2. Binding curves for oligosaccharides 22, 23 and 24. Average fluorescence 
intensities of five replicates were plotted against FGF-2 concentrations. The KD, surf 
values were obtained by fitting the curves to a Langmuir isotherm for a one-site model 
of interaction.     
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Experimental 
General procedures: Thin layer chromatography (TLC) analyses were performed on 
silica gel 60 F254 precoated on aluminium plates (Merck) and the compounds were 
detected by staining with sulfuric acid/ethanol (1:9), with cerium (IV) sulfate 
(10 g), phosphomolybdic acid (13 g), sulfuric acid (60 mL) solution in water (1 L) or 
with anisaldehyde solution (anisaldehyde (25 mL) with sulfuric acid (25 mL), ethanol 
(450 mL) and acetic acid (1 mL)) followed by heating at over 200ºC. Column 
chromatography was carried out on silica gel 60 (0.2-0.5 mm, 0.2-0.063 mm or 0.040-
0.015 mm; Merck). Optical rotations were determined with a Perkin-Elmer 341 
polarimeter. 1H- and 13C-NMR spectra were acquired on Bruker DPX-300, and DRX-
500 spectrometers. Unit A refers to the reducing end monosaccharide in the NMR data. 
Electrospray mass spectra (ESI-MS) were carried out with an Esquire 6000 ESI-Ion 
Trap from Bruker Daltonics. High resolution mass spectra (HR MS) were carried out by 
the Mass Spectrometry Service, CITIUS, Universidad de Sevilla. ESI-MS of final 
compounds 21, 22, 23 and 24 were obtained with a QSTAR mass spectrometer (Applied 
Biosystems) at SIdI, Universidad Autónoma de Madrid. Microwave-based sulfation 
reactions were performed using a Biotage Initiator Eight synthesizer in sealed reaction 
vessels. 
Binding assays in microtiter plates: Oligosaccharides 21-24 and monosaccharide 7 
were dissolved in sodium bicarbonate buffer (50 mM, pH 9.6) containing 
hexadecyltrimethylammonium bromide (1 mM) to afford 10 µM sugar solutions. These 
solutions were transferred to the wells of Nunc Immobilizer AminoTM 384 microtiter 
plates (from Thermo Scientific) (20 µL/well). Blank wells were incubated with 100 mM 
ethanolamine in sodium phosphate buffer (50 mM, pH 9.6) containing 
hexadecyltrimethylammonium bromide (1 mM) (80 µL/well). All samples were 
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performed in replicates of five. The plate was shaken overnight at room temperature and 
the wells were emptied and washed with water. All wells were then blocked by 1 h 
incubation with 100 mM ethanolamine in sodium phosphate buffer and washed with 
water. 20 µL of a recombinant human basic Fibroblast Growth Factor solution (FGF-2, 
from Peprotech, 5 µg/mL in PBS containing 1% BSA) were added to each well. The 
microplate was incubated with gentle agitation at room temperature for 1 h and washed 
with PBS containing 1% Tween 20 and 0.1 % BSA, and water. Rabbit anti-human FGF-
2 antibody (from Peprotech, 5 µg/mL in PBS containing 1% BSA, 20 µL/well) was 
added to the wells. The plate was shaken for 1 h and washed with PBS containing 1% 
Tween 20 and 0.1 % BSA, and water. The primary anti-FGF2 antibody was detected by 
using Alexa Fluor 488 labelled anti-rabbit IgG (from Invitrogen, 20 µg/mL in PBS 
containing 1% BSA, 20 µL/well). The plate was incubated with shaking in the dark for 
1 h and then washed with PBS containing 1% Tween 20 and 0.1 % BSA, and water. 
The fluorescence was read at 535 nm using a TRIAD multimode microplate reader 
(from Dynex). The blank well measurements were subtracted from all values.  
Determination of surface dissociation constants (KD, surf): Oligosaccharides 22-24 
were attached to Nunc Immobilizer AminoTM 384 microplates as described before. The 
wells were incubated with 9 different concentrations of FGF-2, ranging from 581 to 3 
nM. All concentrations and samples were performed in five replicates. The bound 
protein was detected by using the corresponding primary and secondary antibodies as 
above. Data were fitted to a Langmuir equation, assuming a one-site model of the 
interaction.     
 Methyl 4-O-(6-O-acetyl-2-azido-3-O-benzyl-2-deoxy-4-O-levulinoyl-α-D-
glucopyranosyl)-3-O-benzyl-2-O-pivaloyl-α,β-L-idopyranosuronate (3): TMSOTf 
(126 µL, 0.70 mmol) was added under an argon atmosphere at -30ºC to a mixture of 1 
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(10.1 g, 17.4 mmol) and 2 (15.2 g, 34.5 mmol) in dry CH2Cl2 (625 mL). After stirring 
for 30 min at -30ºC, the reaction mixture was neutralized with Et3N and concentrated to 
dryness. The residue was separated by flash column chromatography (hexane/EtOAc 
2:1) to obtain unreacted acceptor (7.2 g, 47%) and fractions containing the desired 
disaccharide; these were combined, concentrated, and dissolved in Py (100 mL). 
Pivaloyl chloride (40 mL) and DMAP (cat.) were added and the solution was stirred at 
room temperature. After 36 h, the mixture was diluted with CH2Cl2, washed with 1 M 
HCl aqueous solution, saturated NaHCO3 aqueous solution and H2O, dried (MgSO4), 
filtered, and concentrated in vacuo. The residue was purified by flash column 
chromatography (hexane/EtOAc 8:1→3:1) to yield the corresponding 2-O-pivaloylated 
disaccharide (7.6 g, 46%; 2 steps). 
An excess of (HF)n·Py (7.6 mL) was added at -15ºC to a solution of this 
disaccharide (1.52 g, 1.61 mmol) in dry THF (40 mL). The reaction was warmed to 
room temperature and stirred for 28 h under an argon atmosphere. The mixture was 
diluted with CH2Cl2 and washed with H2O and saturated NaHCO3 solution until neutral 
pH. The organic layers were dried (MgSO4), filtered and concentrated in vacuo. The 
residue was purified by column chromatography (hexane-EtOAc 1:1) to afford 3 (880 
mg, 68%) as a mixture of α/β anomers. TLC (hexane-EtOAc 1:1) Rf 0.18; 1H-NMR 
(300 MHz, CDCl3) (data for major anomer): δ 7.38-7.28 (m, 10H, Ar), 5.36 (dd, 1H, J1,2 
= 4.4 Hz, J1,OH = 8.6 Hz, H-1A), 5.06 (m, 1H, H-4B), 5.04 (d, 1H, J1,2 = 3.5 Hz, H-1B), 
4.88 (m, 1H, H-2A), 4.80 (m, 1H, H-5A), 4.80-4.62 (m, 4H, CH2(OBn)), 4.19 (dd, 1H, 
J5,6a = 4.5 Hz, J6a,6b = 12.5 Hz, H-6aB), 4.10 (m, 2H, H-3A, H-4A), 4.09 (dd, 1H, J5,6b = 
2.2 Hz, H-6bB), 4.00 (ddd, 1H, J4,5 = 10.3 Hz, H-5B), 3.86 (t, 1H, J2,3 = J3,4 = 10.2 Hz, 
H-3B), 3.80 (s, 3H, COOMe), 3.52 (d, 1H, OH), 3.37 (dd, 1H, H-2B), 2.70 (t, 2H, 
CH2(Lev)), 2.56-2.37 (m, 2H, CH2(Lev)), 2.16 (s, 3H, CH3(Lev)), 2.06 (s, 3H, 
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CH3(Ac)), 1.25 (s, 9H, (CH3)3(Piv)); 
13C-NMR (75 MHz, CDCl3) (data for major 
anomer): δ 206.2 (CO(Lev)), 178.5, 171.6, 170.8, 169.6 (CO(Lev, Ac, Piv, COOMe)), 
137.5, 137.1 (Ar-C), 128.7-128.1 (Ar-CH), 99.0 (C-1B), 93.7 (C-1A), 77.4 (C-3B), 75.6 
(C-4A or C-3A), 74.8, 74.7 (CH2(OBn)), 74.1 (C-4A or C-3A), 71.3 (C-2A), 70.2 
(C-4B), 69.8 (C-5A), 69.2 (C-5B), 63.0 (C-2B), 61.8 (C-6B), 52.5 (COOMe), 39.1 
(C(Piv)), 37.9 (CH2(Lev)), 29.9 (CH3(Lev)), 28.0 (CH2(Lev)), 27.3 ((CH3)3(Piv)), 20.9 
(CH3(Ac)); 
1H-NMR (300 MHz, CDCl3) (selected data for minor anomer): δ 7.38-7.28 
(m, 10H, Ar), 5.22 (dd, 1H, J1,2 = 2.4 Hz, J1,OH = 9.9 Hz, H-1A), 4.97 (d, 1H, J1,2 = 3.8 
Hz, H-1B), 4.94 (dd, 1H, J2,3 = 4.9 Hz, H-2A), 4.80-4.62 (m, 4H, CH2(OBn)), 4.58 (d, 
1H, J4,5 = 3.3 Hz, H-5A), 3.80 (m, 4H, COOMe, OH), 3.40 (dd, 1H, J2,3 = 10.0 Hz, 
H-2B), 1.29 (s, 9H, (CH3)3(Piv)); 
13C-NMR (75 MHz, CDCl3) (selected data for minor 
anomer): δ 128.7-127.8 (Ar-CH), 98.6 (C-1B), 92.7 (C-1A), 75.0-74.7 (CH2(OBn)), 
73.6 (C-5A), 70.3 (C-2A), 52.8 (COOMe), 39.2 (C(Piv)), 27.4 ((CH3)3(Piv)), 20.9 
(CH3(Ac)); HR MS: m/z: calcd for C39H49N3O15Na: 822.3061; found: 822.3064 
[M+Na]+.  
O-(Methyl 4-O-(6-O-acetyl-2-azido-3-O-benzyl-2-deoxy-4-O-levulinoyl-α-D-
glucopyranosyl)-3-O-benzyl-2-O-pivaloyl-α,β-L-idopyranosyluronate) 
trichloroacetimidate (4): K2CO3 (83 mg, 0.61 mmol) and trichloroacetonitrile (0.82 
mL, 8.25 mmol) were added at room temperature to a solution of 3 (440 mg, 0.55 
mmol) in dry CH2Cl2 (5 mL). After stirring for 6 h at room temperature, the reaction 
mixture was filtered through a pad of Celite and concentrated to dryness. The residue 
was purified by column chromatography (hexane-EtOAc 2:1 + 1% Et3N) to yield 4 (460 
mg, 88%). TLC (hexane-EtOAc 1:1) Rf 0.44, 0.51 (α and β anomers); 1H-NMR (300 
MHz, CDCl3) (data for major anomer): δ 8.72 (s, 1H, NH), 7.36-7.25 (m, 10H, Ar), 6.42 
(d, 1H,  J1,2 = 2.1 Hz,  H-1A), 5.20 (bt, 1H, H-2A), 5.10 (bt, 1H, J3,4 = J4,5 = 9.6 Hz, 
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H-4B), 5.04 (d, 1H, J1,2 = 3.5 Hz, H-1B), 4.92 (d, 1H, J4,5 = 3.0 Hz, H-5A), 4.86-4.63 
(m, 4H, CH2(OBn)), 4.25-4.03 (m, 4H, H-4A, H-6aB, H-6bB, H-3A), 4.01 (m, 1H, 
H-5B), 3.90 (t, 1H, J2,3 = J3,4 = 9.2 Hz, H-3B), 3.80 (s, 3H, COOMe), 3.40 (dd, 1H, 
H-2B), 2.70 (m, 2H, CH2(Lev)), 2.56-2.37 (m, 2H, CH2(Lev)), 2.17 (s, 3H, CH3(Lev)), 
2.04 (s, 3H, CH3(Ac)), 1.28 (s, 9H, (CH3)3(Piv)); 
13C-NMR (75 MHz, CDCl3) (data for 
major anomer): δ 206.2 (CO(Lev)), 177.6, 171.6, 170.8, 168.8, (CO(Lev, Ac, Piv, 
COOMe)), 160.3 (C=NH), 137.5, 137.2 (Ar-C), 128.6-127.7 (Ar-CH), 98.6 (C-1B), 
95.6 (C-1A), 90.8 (CCl3), 77.5 (C-3B), 74.7, 73.3 (CH2(OBn)), 74.2 (C-4A), 74.1 
(C-3A), 70.0 (C-4B), 69.8 (C-5A), 69.2 (C-5B), 67.2 (C-2A), 63.0 (C-2B), 61.5 (C-6B), 
52.5 (COOMe), 39.0 (C(Piv)), 37.9(CH2(Lev)), 29.9 (CH3(Lev)), 27.9 (CH2(Lev)), 27.3 
((CH3)3(Piv)), 20.7 (CH3(Ac)); 
1H-NMR (300 MHz, CDCl3) (selected data for minor 
anomer): δ 8.66 (s, 1H, NH), 7.36-7.25 (m, 10H, Ar), 6.35 (d, 1H,  J1,2 = 2.7 Hz,  
H-1A), 5.24 (dd, 1H, J2,3 = 5.6 Hz, H-2A), 5.00 (d, 1H, J1,2 = 3.7 Hz, H-1B), 4.86-4.63 
(m, 5H, H-5A, CH2(OBn)), 4.33 (t, 1H, H-3A), 3.79 (s, 3H, COOMe), 3.44 (dd, 1H, H-
2B), 2.70 (m, 2H, CH2(Lev)), 2.56-2.37 (m, 2H, CH2(Lev)), 2.15 (s, 3H, CH3(Lev)), 
2.05 (s, 3H, CH3(Ac)), 1.25 (s, 9H, (CH3)3(Piv)); 
13C-NMR (75 MHz, CDCl3) (selected 
data for minor anomer): δ 99.5 (C-1B), 94.8 (C-1A), 74.6 (C-3A), 68.1 (C-2A), 63.3 (C-
2B), 52.3 (COOMe), 39.1 (C(Piv)), 37.9 (CH2(Lev)), 29.9 (CH3(Lev)), 27.9 
(CH2(Lev)), 27.3 ((CH3)3(Piv)), 20.7 (CH3(Ac)); ESI MS: m/z: calcd for 
C41H49Cl3N4O15Na: 965.2; found: 965.7 [M+Na]
+. 
(4-O-(6-O-acetyl-2-azido-3-O-benzyl-2-deoxy-4-O-levulinoyl-α-D-glucopyranosyl)-
3-O-benzyl-2-O-pivaloyl-β-L-idopyranosyl)-6,1-lactone (5): TLC (hexane-EtOAc 
1:1) Rf 0.57; 
1H-NMR (300 MHz, CDCl3): δ 7.37-7.24 (m, 10H, Ar), 5.86 (d, 1H, J1,2 = 
2.1 Hz, H-1A), 5.14 (d, 1H, J1,2 = 3.9 Hz, H-1B), 5.09 (dd, 1H, J3,4 = 9.3 Hz, J4,5 = 10.2 
Hz, H-4B), 5.01 (d, 1H, CH2(OBn)), 4.96 (dt, 1H, J2,3 = 6.0 Hz, J2,4 = 1.8 Hz, H-2A), 
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4.76 (m, 2H, CH2(OBn)), 4.73 (m, 2H, H-4A, H-5A), 4.66 (d, 1H, CH2(OBn)), 4.40 
(ddd, 1H, J5,6a = 5.1 Hz, J5,6b = 2.1 Hz, H-5B), 4.23 (dd, 1H, J6a,6b = 12.3 Hz, H-6aB), 
4.13 (dd, 1H, H-6bB), 3.95 (m, 2H, H-3A, H-3B), 3.60 (dd, 1H, J2,3 = 10.2 Hz, H-2B), 
2.71 (t, 2H, CH2(Lev)), 2.50 (m, 2H, CH2(Lev)), 2.17 (s, 3H, CH3(Lev)), 2.05 (s, 3H, 
CH3(Ac)), 1.24 (s, 9H, (CH3)3(Piv)); 
13C-NMR (75 MHz, CDCl3): δ 206.2 (CO(Lev)), 
177.8, 171.7, 170.5, 169.4 (CO(Ac, Lev, Piv, lactone)), 137.6, 137.5, 128.6, 128.2, 
128.1, 127.8 (Ar), 100.6 (C-1B), 100.3 (C-1A), 79.4 (C-3A), 77.9 (C-3B), 75.9, 75.4 
(CH2(OBn)), 73.5 (C-2A), 70.9 (C-4A, C-5A), 70.5 (C-4B), 69.1 (C-5B), 63.5 (C-2B), 
62.4 (C-6B), 39.0 (C(Piv)), 37.9 (CH2(Lev)), 29.9 (CH3(Lev)), 28.0 (CH2(Lev)), 27.1 
((CH3)3(Piv)), 20.9 (CH3(Ac)); ESI MS: m/z: calcd for C38H45N3O14Na: 790.3; found: 
790.2 [M+Na]+. 
Methyl (N-benzyloxycarbonyl-2-aminoethyl 4-O-(6-O-acetyl-2-azido-3-O-benzyl-2-
deoxy-4-O-levulinoyl-α-D-glucopyranosyl)-3-O-benzyl-2-O-pivaloyl-α-L-
idopyranoside) uronate (8): TMSOTf (170 µL of a 0.092 M solution in dry CH2Cl2) 
was added under an argon atmosphere at 0ºC to a mixture of 4 (280 mg, 0.30 mmol) and 
benzyl N-(2-hydroxyethyl)-carbamate (116 mg, 0.593 mmol) in dry CH2Cl2 (1.5 mL). 
After stirring for 15 min at 0ºC, the reaction mixture was neutralized with Et3N and 
concentrated to dryness. The residue was purified by column chromatography (toluene-
EtOAc 3:2) to afford 8 (224 mg, 77%). TLC (toluene-EtOAc 3:2) Rf 0.3; 
1H-NMR (300 
MHz, CDCl3): δ 7.36-7.28 (m, 15 H, Ar), 5.17 (bt, 1H, NH), 5.08 (m, 5H, H-1A, H-1B, 
H-4B, CH2(Z)), 4.95 (t, 1H, J1,2 = J2,3 = 4.5 Hz, H-2A), 4.79-4.70 (m, 4H, CH2(OBn), 
H-5A (4.73)), 4.65 (d, 1H, CH2(OBn)), 4.19 (dd, 1H, J5,6a = 4.2 Hz, J6a,6b = 12.6 Hz, 
H-6aB), 4.14 (t, 1H, J3,4 = J4,5 = 4.8 Hz, H-4A), 4.08 (dd, 1H, J5,6b = 2.1 Hz, H-6bB), 
4.00 (ddd, 1H, J4,5 = 10.2 Hz, H-5B), 3.96 (t, 1H, H-3A), 3.87 (t, 1H, J2,3 = J3,4 = 10.2 
Hz, H-3B), 3.78 (m, 4H, COOMe, CH2-O), 3.63 (m, 1H, CH2-O), 3.41 (m, 2H, CH2-N), 
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3.35 (dd, 1H, J1,2 = 3.6 Hz, H-2B), 2.70 (t, 2H, CH2(Lev)), 2.46 (m, 2H, CH2(Lev)), 
2.16 (s, 3H, CH3(Lev)), 2.04 (s, 3H, CH3(Ac)), 1.22 (s, 9H, (CH3)3(Piv)); 
13C-NMR (75 
MHz, CDCl3): δ 206.2 (CO(Lev)), 177.6, 171.6, 170.7, 169.7 (CO(Lev, Ac, Piv, 
COOMe)), 156.5 (CO(Z)), 137.5-136.6 (Ar-C), 128.6-127.7 (Ar-CH), 99.2 (C-1A), 98.3 
(C-1B), 77.4 (C-3B), 75.4 (C-3A), 74.8 (CH2(OBn)), 74.1 (C-4A), 73.3 (CH2(OBn)), 
70.2 (CH2(Z)), 70.0 (C-2A), 69.7 (C-5A), 69.1 (C-5B), 68.3 (CH2-O), 66.9 (C-4B), 62.9 
(C-2B), 61.8 (C-6B), 52.5 (COOMe), 40.9 (CH2-N), 38.9 (C(Piv)), 37.9 (CH2(Lev)), 
29.8 (CH3(Lev)), 27.9 (CH2(Lev)), 27.2 ((CH3)3(Piv)), 20.9 (CH3(Ac)); HR MS: m/z: 
calcd for C49H60N4O17Na: 999.3851; found: 999.3880 [M+Na]
+. 
Methyl (N-benzyloxycarbonyl-2-aminoethyl 4-O-(6-O-acetyl-2-azido-3-O-benzyl-2-
deoxy-α-D-glucopyranosyl)-3-O-benzyl-2-O-pivaloyl-α-L-idopyranoside) uronate 
(9): Compound 8 (250 mg, 0.26 mmol) was dissolved in CH2Cl2 (1.7 mL) and 
hydrazine monohydrate (1.0 mL of a 0.5 M solution in Py/AcOH 3:2) was added. After 
stirring at room temperature for 2h, the reaction mixture was quenched with acetone 
(1.5 mL). The mixture was diluted with CH2Cl2 and washed with H2O. The organic 
layer was dried (MgSO4), filtered and concentrated in vacuo. The residue was purified 
by column chromatography (hexane-EtOAc 1:1) to yield 9 (204 mg, 91%). TLC 
(hexane-EtOAc 1:1) Rf 0.5; [α]
20
D  +1º (c 1.2, CH2Cl2); 
1H-NMR (300 MHz, CDCl3): δ 
7.42-7.29 (m, 15 H, Ar), 5.19 (bt, 1H, NH), 5.08 (m, 3H, H-1A, CH2(Z)), 5.03 (d, 1H, 
J1,2 = 3.3 Hz, H-1B), 4.95 (t, 1H, J1,2 = J2,3 = 4.5 Hz, H-2A), 4.85 (m, 2H, CH2(OBn)), 
4.75 (m, 2H, CH2(OBn)), 4.72 (d, 1H, J4,5 = 4.2 Hz, H-5A), 4.55 (dd, 1H, J5,6a = 3.6 Hz, 
J6a,6b = 12.6 Hz, H-6aB), 4.17 (dd, 1H, J5,6b = 2.0 Hz, H-6bB), 4.12 (t, 1H, H-4A), 3.97 
(t, 1H, J3,4 = 5.1 Hz, H-3A), 3.81 (m, 2H, H-5B, CH2-O), 3.77 (s, 3H, COOMe), 3.72 
(dd, 1H, J2,3 = 10.2 Hz, J3,4 = 9.0 Hz, H-3B), 3.63 (m, 1H, CH2-O), 3.47 (m, 1H, H-4B), 
3.41 (m, 2H, CH2-N), 3.23 (dd, 1H, H-2B), 2.09 (s, 3H, CH3(Ac)), 1.21 (s, 9H, 
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(CH3)3(Piv)); 
13C-NMR (75 MHz, CDCl3): δ 177.7, 172.1, 169.8 (CO(Ac, Piv, 
COOMe)), 156.5 (CO(Z)), 137.9-136.6 (Ar-C), 128.8-127.7 (Ar-CH), 99.1 (C-1A), 98.6 
(C-1B), 78.9 (C-3B), 75.6 (C-3A), 75.3 (CH2(OBn)), 74.0 (C-4A), 73.3 (CH2(OBn)), 
71.2 (C-5B), 70.6 (C-4B), 70.1 (C-2A), 70.0 (C-5A), 68.4 (CH2-O), 66.8 (CH2(Z)), 62.8 
(C-2B, C-6B), 52.5 (COOMe), 40.9 (CH2-N), 38.9 (C(Piv)), 27.2 ((CH3)3(Piv)), 20.9 
(CH3(Ac)); HR MS: m/z: calcd for C44H54N4O15Na: 901.3483; found: 901.3514 
[M+Na]+. 
N-Benzyloxycarbonyl-2-aminoethyl (6-O-acetyl-2-azido-3-O-benzyl- 
2-deoxy-4-O-levulinoyl-α-D-glucopyranosyl)-(1→4)-(methyl 3-O-benzyl-2-O-
pivaloyl-α-L-idopyranosyluronate)-(1→4)-(6-O-acetyl-2-azido-3-O-benzyl-2-deoxy-
α-D-glucopyranosyl)-(1→4)-methyl 3-O-benzyl-2-O-pivaloyl-α-L-
idopyranosiduronate (10): TMSOTf (305 µL of a 0.18 M solution in dry CH2Cl2) was 
added under an argon atmosphere at 0ºC to a mixture of 9 (107 mg, 0.122 mmol) and 4 
(172 mg, 0.183 mmol) in dry CH2Cl2 (1.2 mL). After stirring for 20 min at 0ºC, the 
reaction mixture was neutralized with Et3N and concentrated to dryness. The residue 
was purified by column chromatography (toluene-EtOAc 4:1→2:1) to afford 10 (150 
mg, 74%), unreacted 9 (25 mg, 23%) and 11 (42 mg, 0.054 mmol). TLC (hexane-
EtOAc 2:3) Rf 0.57; [α]
20
D  +8º (c 0.9, CH2Cl2); 
1H-NMR (500 MHz, CDCl3): δ 
7.34-7.25 (m, 25H, Ar), 5.26 (d, 1H, J1,2 = 5.0 Hz, H-1C), 5.16 (bt, 1H, NH), 5.11 (d, 
1H, J1,2 = 4.5 Hz, H-1A), 5.10-5.06 (m, 3H, H-4D, CH2(Z)), 5.05 (d, 1H, J1,2 = 3.6 Hz, 
H-1D), 5.03 (d, 1H, J1,2 = 3.6 Hz, H-1B), 4.98 (t, 1H, J2,3 = 5.0 Hz, H-2C), 4.94-4.92 (m, 
2H, H-2A, CH2(OBn)), 4.80-4.63 (m, 9H, CH2(OBn), H-5A (4.67), H-5C (4.65)), 
4.36-4.30 (m, 2H, H-6aB, H-6bB), 4.16 (dd, 1H, J5,6a = 4.0 Hz, J6a,6b = 12.5 Hz, H-6aD), 
4.11 (t, 1H, J3,4 = J4,5 = 5.0 Hz, H-4A), 4.07 (t, 1H, J3,4 = J4,5 = 5.0 Hz, H-4C), 4.02 (dd, 
1H, J5,6b = 2.0 Hz, H-6bD), 3.96-3.93 (m, 5H, H-3A, H-3C, H-4B, H-5B, H-5D), 
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3.84-3.80 (m, 2H, H-3D, CH2-O), 3.75-3.70 (m, 4H, H-3B, COOMe), 3.64-3.59 (m, 4H, 
COOMe, CH2-O), 3.40 (m, 2H, CH2-N), 3.35 (dd, 1H, J2,3 = 10.3 Hz, H-2D), 3.29 (dd, 
1H, J2,3 = 10.3 Hz, H-2B), 2.74-2.66 (m, 2H, CH2(Lev)), 2.52-2.36 (m, 2H, CH2(Lev)), 
2.16 (s, 3H, CH3(Lev)), 2.11, 1.99 (2s, 6H, CH3(Ac)), 1.22, 1.21 (2s, 18H, (CH3)3(Piv)); 
13C-NMR (125 MHz, CDCl3): δ 206.1 (CO(Lev)), 177.6, 177.3, 171.5, 170.7, 170.6, 
169.8, 169.5 (CO(Lev, Ac, Piv, COOMe)), 156.4 (CO(Z)), 137.8-136.6 (Ar-C), 
129.1-127.5 (Ar-CH), 99.1 (C-1A), 98.4 (C-1D), 98.1 (C-1B), 98.0 (C-1C), 78.1 
(C-3B), 77.4 (C-3D), 76.0 (C-3C), 75.9 (C-3A), 75.0 (C-4B, CH2(OBn)), 74.7 
(CH2(OBn)), 74.0 (C-4C), 73.8 (C-4A), 73.7 (CH2(OBn)), 73.5 (CH2(OBn)), 70.5 
(C-2C), 70.4 (C-2A, C-5C), 70.3 (C-5A), 70.0 (CH2(Z)), 69.8 (C-5B), 69.0 (C-5D), 68.4 
(CH2-O), 66.8 (C-4D), 63.0 (C-2B), 62.9 (C-2D), 62.1 (C-6B), 61.6 (C-6D), 52.4, 52.1 
(COOMe), 40.9 (CH2-N), 38.9 (C(Piv)), 37.8 (CH2(Lev)), 29.8 (CH3(Lev)), 27.9 
(CH2(Lev)),  27.2, 27.1 ((CH3)3(Piv)), 20.9, 20.8 (CH3(Ac)); HR MS: m/z: calcd for 
C83H101N7O29Na: 1682.6541; found: 1682.6498 [M+Na]
+. 
Methyl 4-O-(6-O-acetyl-2-azido-3-O-benzyl-2-deoxy-4-O-levulinoyl-α-D-
glucopyranosyl)-1,5-anhydro-3-O-benzyl-2-O-pivaloyl-L-xylo-hex-1- 
enitoluronate (11): TLC (toluene-EtOAc 2:1) Rf 0.33; [α]
20
D  +6º (c 1.0, CHCl3); 
1H-NMR (500 MHz, CDCl3): δ 7.38-7.25 (m, 10H, Ar), 6.79 (s, 1H, H-1A), 5.07 (dd, 
1H, J3,4 = J4,5 = 9.7 Hz, H-4B), 4.98 (d, 1H, J1,2 = 3.3 Hz, H-1B), 4.79 (d, 1H, 
CH2(OBn)), 4.67 (bs, 2H, CH2(OBn)), 4.65 (d, 1H, CH2(OBn)), 4.58 (bs, 1H, H-5A), 
4.35 (m, 1H, H-4A), 4.19 (dd, 1H, J5,6a = 4.0 Hz, J6a,6b = 12.1 Hz, H-6aB), 4.19 (bd, 1H, 
J3,4 = 1.9 Hz, H-3A), 4.09 (dd, 1H, J5,6b = 2.1 Hz, H-6bB), 3.96 (dd, 1H, J2,3 = 9.8 Hz, 
H-3B), 3.83 (m, 4H,  H-5B, COOMe), 3.35 (dd, 1H, H-2B), 2.72-2.29 (m, 4H, 
CH2(Lev)), 2.15 (s, 3H, CH3(Lev)), 2.06 (s, 3H, CH3(Ac)), 1.24 (s, 9H, (CH3)3(Piv)); 
13C-NMR (75 MHz, CDCl3) (Significant data from HMQC experiment): δ 138.6 
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(C-1A), 97.6 (C-1B), 77.0 (C-3B), 74.5 (CH2(OBn)), 73.2 (C-4A), 72.0 (C-5A), 71.9 
(CH2(OBn)), 69.6 (C-4B, C-3A), 69.0 (C-5B), 62.7 (C-2B), 61.4 (C-6B), 52.5 
(COOMe), 38.2 (CH2(Lev)), 29.5 (CH3(Lev)), 28.4 (CH2(Lev)), 26.9 ((CH3)3(Piv)), 
20.7 (CH3(Ac)); ESI MS: m/z: calcd for C39H47N3O14Na: 804.3; found: 804.1 [M+Na]
+; 
HR MS: m/z: calcd for C39H47N3O14Na: 804.2956; found: 804.2982 [M+Na]
+. 
N-Benzyloxycarbonyl-2-aminoethyl (6-O-acetyl-2-azido-3-O-benzyl- 
2-deoxy-α-D-glucopyranosyl)-(1→4)-(methyl 3-O-benzyl-2-O-pivaloyl-α-L-
idopyranosyluronate)-(1→4)-(6-O-acetyl-2-azido-3-O-benzyl-2-deoxy-α-D-
glucopyranosyl)-(1→4)-methyl 3-O-benzyl-2-O-pivaloyl-α-L-idopyranosiduronate 
(12): Compound 10 (110 mg, 0.066 mmol) was dissolved in CH2Cl2 (1.0 mL) and 
hydrazine monohydrate (0.26 mL of a 0.5 M solution in Py/AcOH 3:2) was added. After 
stirring at room temperature for 2 h, the reaction mixture was quenched with acetone 
(0.5 mL). The mixture was diluted with CH2Cl2 and washed with H2O. The organic 
layer was dried (MgSO4), filtered and concentrated in vacuo. The residue was purified 
by column chromatography (toluene-EtOAc 5:2) to yield 12 (85 mg, 82%). TLC 
(hexane-EtOAc 2:3) Rf 0.63; [α]
20
D  –2º (c 1.0, CHCl3); 
1H-NMR (300 MHz, CDCl3): δ 
7.41-7.28 (m, 25H, Ar), 5.29 (d, 1H, J1,2 = 4.6 Hz, H-1C), 5.14 (bt, 1H, NH), 5.11 (d, 
1H, J1,2 = 4.7 Hz, H-1A), 5.09 (m, 2H, CH2(Z)), 5.04-5.00 (m, 2H, H-1D, H-1B), 
4.99-4.96 (m, 1H, H-2C), 4.95-4.91 (m, 2H, H-2A, CH2(OBn)), 4.89-4.82 (m, 2H, 
CH2(OBn)), 4.81-4.66 (m, 6H, CH2(OBn), H-5A (4.67)), 4.60 (d, 1H, J4,5 = 4.9 Hz, 
H-5C), 4.51 (dd, 1H, J5,6a = 3.2 Hz, J6a,6b = 12.5 Hz, H-6aD), 4.32 (m, 2H, H-6aB, 
H-6bB), 4.13-4.06 (m, 3H, H-4A, H-4C, H-6bD), 3.99-3.93 (m, 4H, H-3A, H-3C, 
H-4B, H-5B), 3.85-3.76 (m, 2H, H-5D, CH2-O), 3.76-3.71 (m, 4H, H-3D, COOMe), 
3.68 (dd, 1H, J2,3 = 10.2 Hz, J3,4 = 8.7 Hz, H-3B), 3.64-3.57 (m, 4H, COOMe, CH2-O), 
3.48-3.36 (m, 3H, H-4D, CH2-N), 3.29 (dd, 1H, J1,2 = 3.6 Hz, J2,3 = 10.2 Hz, H-2D), 
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3.23 (dd, 1H, J1,2 = 3.6 Hz, H-2B), 2.90 (m, 1H, OH), 2.11, 2.06 (2s, 6H, CH3(Ac)), 
1.22, 1.19 (2s, 18H, (CH3)3(Piv)); 
13C-NMR (75 MHz, CDCl3): δ 177.6, 177.3, 172.0, 
170.9, 169.9, 169.7 (CO(Ac, Piv, COOMe)), 156.5 (CO(Z)), 137.9-136.7 (Ar-C), 
128.8-127.6 (Ar-CH), 99.2, 99.0, (C-1A, C-1B or C-1D), 98.1, 98.0 (C-1C, C-1B or 
C-1D), 78.7 (C-3B), 77.9 (C-3D), 76.0 (C-3C, C-3A), 75.0 (C-4B, CH2(OBn)), 74.0, 
73.7 (C-4C, C-4A), 73.5 (CH2(OBn)), 71.0 (C-5D), 70.8 (C-2C, C-5C), 70.4 (C-2A, 
C-4D), 70.2 (C-5A), 69.7 (C-5B), 68.2 (CH2-O), 66.7 (CH2(Z)), 62.8 (C-2B, C-2D), 
62.4 (C-6D), 62.0 (C-6B), 52.2, 51.8 (COOMe), 40.8 (CH2-N), 39.0 (C(Piv)), 27.3, 27.2 
((CH3)3(Piv)), 20.9 (CH3(Ac)); HR MS: m/z: calcd for C78H95N7O27Na: 1584.6174; 
found: 1584.6115 [M+Na]+. 
N-Benzyloxycarbonyl-2-aminoethyl (6-O-acetyl-2-azido-3-O-benzyl- 
2-deoxy-4-O-levulinoyl-α-D-glucopyranosyl)-(1→4)-(methyl 3-O-benzyl-2-O-
pivaloyl-α-L-idopyranosyluronate)-(1→4)-(6-O-acetyl-2-azido-3-O-benzyl-2-deoxy-
α-D-glucopyranosyl)-(1→4)-(methyl 3-O-benzyl-2-O-pivaloyl-α-L-
idopyranosyluronate)-(1→4)-(6-O-acetyl-2-azido-3-O-benzyl-2-deoxy-α-D-
glucopyranosyl)-(1→4)-methyl 3-O-benzyl-2-O-pivaloyl-α-L-idopyranosiduronate 
(13): TMSOTf (157 µL of a 0.18 M solution in dry CH2Cl2) was added under an argon 
atmosphere at 0ºC to a mixture of 12 (135 mg, 0.086 mmol) and 4 (133 mg, 0.14 mmol) 
in dry CH2Cl2 (1.0 mL). After stirring for 20 min at 0ºC, the reaction mixture was 
neutralized with Et3N and concentrated to dryness. The residue was purified by column 
chromatography (hexane-EtOAc 2:1→3:2) to afford 13 (123 mg, 61%), unreacted 12 
(38 mg, 28%) and 11 (30 mg, 0.039 mmol). TLC (hexane-EtOAc 1:1) Rf 0.22; [α]
20
D  
+5º (c 1.1, CH2Cl2); 
1H-NMR (500 MHz, CDCl3): δ 7.37-7.26 (m, 35 H, Ar), 5.37 (d, 
1H, J1,2 = 6.1 Hz, H-1E), 5.28 (d, 1H, J1,2 = 5.1 Hz, H-1C), 5.16 (bt, 1H, NH), 5.12 (d, 
1H, J1,2 = 4.7 Hz, H-1A), 5.10-5.08 (m, 3H, H-4F, CH2(Z)), 5.06-5.03 (m, 3H, H-1B, 
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H-1D, H-1F), 5.00 (t, 1H, J2,3 = 6.4 Hz, H-2E), 4.99 (t, 1H, J2,3 = 5.5 Hz, H-2C), 
4.95-4.90 (m, 3H, H-2A, CH2(OBn)), 4.85-4.64 (m, 11H, CH2(OBn), H-5A (4.65)), 
4.62 (d, 1H, J4,5 = 4.5 Hz, H-5C), 4.50 (d, 1H, J4,5 = 5.7 Hz, H-5E), 4.35-4.27 (m, 4H, 
H-6aB, H-6bB, H-6aD, H-6bD), 4.16 (dd, 1H, J5,6a = 4.2 Hz, J6a,6b = 12.6 Hz, H-6aF), 
4.11 (dd,1H, J3,4 = J4,5 = 5.4 Hz, H-4A), 4.07 (dd,1H, J3,4 = J4,5 = 5.4Hz, H-4C), 4.03 (m, 
1H, H-4E), 4.01 (dd, 1H, J5,6b = 2.1 Hz, H-6bF), 3.96-3.88 (m, 8H, H-3A, H-3C, H-3E, 
H-4B, H-4D, H-5B, H-5D, H-5F), 3.84-3.78 (m, 2H, H-3F, CH2-O), 3.75 (s, 3H, 
COOMe), 3.71 (dd, 1H, J2,3 = 10.4 Hz, J3,4 = 8.4 Hz, H-3B or H-3D), 3.63 (dd, 1H, J2,3 = 
10.3 Hz, J3,4 = 8.7 Hz, H-3B or H-3D), 3.61 (m, 4H, COOMe, CH2-O), 3.60 (s, 3H, 
COOMe), 3.44-3.34 (m, 2H, CH2-N), 3.36 (dd, 1H, J2,3 = 10.2 Hz, H-2F), 3.32-3.28 
(2dd, 2H, H-2B and H-2D), 2.74-2.65 (m, 2H, CH2(Lev)), 2.53-2.35 (m, 2H, 
CH2(Lev)), 2.16 (s, 3H, CH3(Lev)), 2.11, 2.08, 1.99 (3s, 9H, CH3(Ac)), 1.21, 1.19 (3s, 
27H, (CH3)3(Piv)); 
13C-NMR (125 MHz, CDCl3): δ 206.2 (CO(Lev)), 177.6, 177.3, 
177.2, 170.5-169.6 (CO(Lev, Ac, Piv, COOMe)), 156.6 (CO(Z)), 137.9-136.7 (Ar-C), 
128.6-127.3 (Ar-CH), 99.2 (C-1A), 98.4, 98.3, 98.1 (C-1B, C-1D, C-1F), 97.9 (C-1C), 
97.7 (C-1E), 78.1, 77.9 (C-3B, C-3D), 77.5 (C-3F), 77.0-75.8 (C-3A, C-3C, C-3E), 75.2 
(CH2(OBn)), 74.9 (C-4B, C-4D), 74.8 (CH2(OBn)), 74.3, 73.8 (CH2(OBn)), 74.2 
(C-4C), 74.0 (C-4E), 73.6 (C-4A), 71.5 (C-2E, C-5E), 71.1 (C-2C), 70.8 (C-5C), 70.6 
(C-2A), 70.5 (C-5A), 69.8 (C-5B, C-5D, CH2(Z)), 69.0 (C-5F), 68.5 (CH2-O), 66.9 (C-
4F), 63.0 (C-2B, C-2D), 62.9 (C-2F), 62.0 (C-6B, C-6D), 61.7 (C-6F), 52.5, 52.1 
(COOMe), 40.9 (CH2-N), 39.0 (C(Piv)), 37.9 (CH2(Lev)), 29.9 (CH3(Lev)), 27.9 
(CH2(Lev)) 27.3, 27.2 ((CH3)3(Piv)), 20.9, 20.8 (CH3(Ac)); ESI MS: m/z: calcd for 
C117H142N10O41Na: 2365.9; found: 2366.4 [M+Na]
+. 
N-Benzyloxycarbonyl-2-aminoethyl (6-O-acetyl-2-azido-3-O-benzyl- 
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2-deoxy-α-D-glucopyranosyl)-(1→4)-(methyl 3-O-benzyl-2-O-pivaloyl-α-L-
idopyranosyluronate)-(1→4)-(6-O-acetyl-2-azido-3-O-benzyl-2-deoxy-α-D-
glucopyranosyl)-(1→4)-(methyl 3-O-benzyl-2-O-pivaloyl-α-L-
idopyranosyluronate)-(1→4)-(6-O-acetyl-2-azido-3-O-benzyl-2-deoxy-α-D-
glucopyranosyl)-(1→4)-methyl 3-O-benzyl-2-O-pivaloyl-α-L-idopyranosiduronate 
(14): Compound 13 (119 mg, 0.051 mmol) was dissolved in CH2Cl2 (1.0 mL) and 
hydrazine monohydrate (0.197 mL of a 0.5 M solution in Py/AcOH 3:2) was added. 
After stirring at room temperature for 2h, the reaction mixture was quenched with 
acetone (0.5 mL). The mixture was diluted with CH2Cl2 and washed with H2O. The 
organic layer was dried (MgSO4), filtered and concentrated in vacuo. The residue was 
purified by column chromatography (hexane-EtOAc 3:2) to yield 14 (100 mg, 87%). 
TLC (hexane-EtOAc 1:1) Rf 0.33; 
1H-NMR (500 MHz, CDCl3): δ 7.40-7.25 (m, 35 H, 
Ar), 5.38 (d, 1H, J1,2 = 6.1 Hz, H-1E), 5.31 (d, 1H, J1,2 = 5.5 Hz, H-1C), 5.16 (bt, 1H, 
NH), 5.12 (d, 1H, J1,2 = 4.8 Hz, H-1A), 5.12 (m, 2H, CH2(Z)), 5.04-5.02 (m, 3H, H-1B, 
H-1D, H-1F), 5.02-4.98 (m, 2H, H-2E, H-2C), 4.96-4.92 (m, 3H, H-2A,CH2(OBn)), 
4.87-4.68 (m, 10H, CH2(OBn)), 4.65 (d, 1H, J4,5 = 4.6 Hz, H-5A), 4.58 (d, 1H, J4,5 = 5.1 
Hz, H-5C), 4.53-4.48 (m, 2H, H-6aF, H-5E), 4.36-4.26 (m, 4H, H-6aB, H-6bB, H-6aD, 
H-6bD), 4.13-4.02 (m, 4H, H-6bF, H-4A, H-4C, H-4E), 3.99-3.87 (m, 8H, H-3A, H-3C, 
H-3E, H-4B, H-4D, H-5B, H-5D, H-5F), 3.84-3.56 (m, 14H, H-3F, H-3B, H-3D, 
CH2-O, COOMe (3.79, 3.62)), 3.47-3.33 (m, 3H, H-4F, CH2-N), 3.33-3.22 (3dd, 3H, 
H-2F, H-2B, H-2D), 2.93 (bd, 1H, OH), 2.11, 2.07, 2.06 (3s, 9H, CH3(Ac)), 1.20, 1.19 
(3s, 27H, (CH3)3(Piv)); 
13C-NMR (125 MHz, CDCl3): δ 177.6, 177.3, 177.2, 172.0, 
170.9, 170.8, 170.0, 169.9, 169.7 (CO(Ac, Piv, COOMe)), 156.5 (CO(Z)), 137.9-136.6 
(Ar-C), 128.8-127.2 (Ar-CH), 99.1 (C-1A), 99.0, 98.3, 98.0 (C-1B, C-1D, C-1F), 97.8 
(C-1C), 97.7 (C-1E), 79.0 (C-3F), 78.1, 77.9 (C-3B, C-3D), 76.9-76.4 (C-3A, C-3C, 
 31 
C-3E), 75.3 (CH2(OBn), C-4B or C-4D), 75.0 (C-4B or C-4D), 74.9 (CH2(OBn)), 74.4, 
73.9 (C-4A or C-4C or C-4E), 73.8 (CH2(OBn)), 73.6 (C-4A or C-4C or C-4E, 
CH2(OBn)), 71.6 (C-5E, C-2C or C-2E), 71.3 (C-2C or C-2E), 71.2 (C-5C, C-5F), 70.5 
(C-2A, C-5A, C-4F), 69.8 (C-5B, C-5D), 68.5 (CH2-O), 66.8 (CH2(Z)), 62.9 (C-2B, 
C-2D, C-2F), 62.6 (C-6F), 62.0 (C-6B, C-6D), 52.5, 52.1 (COOMe), 40.9 (CH2-N), 
39.0 (C(Piv)), 27.3, 27.2 ((CH3)3(Piv)), 20.9 (CH3(Ac)); ESI MS: m/z: calcd for 
C112H136N10O39Na: 2267.9; found: 2268.3 [M+Na]
+. 
Methyl (N-benzyloxycarbonyl-2-aminoethyl 4-O-(6-O-acetyl-2-azido-3,4-di-O-
benzyl-2-deoxy-α-D-glucopyranosyl)-3-O-benzyl-2-O-pivaloyl-α-L-idopyranoside) 
uronate (15): Benzyl bromide (40 µL, 0.34 mmol) was added under an argon 
atmosphere at 0ºC to a solution of 9 (30 mg, 0.034 mmol) and freshly prepared Ag2O 
(18 mg, 0.079 mmol) in dry DMF (0.5 mL). After stirring for 8 h at room temperature, 
the solution was filtered through Celite, diluted with EtOAc and washed with H2O. The 
organic layer was dried (MgSO4), filtered and concentrated in vacuo. The residue was 
purified by column chromatography (hexane-EtOAc 1:0 → 2:1) to afford 15 (8 mg, 
25%) and unreacted 9 (8 mg, 27%). TLC (hexane-EtOAc 3:2) Rf 0.4; [α]
20
D  +8º (c 1.0, 
CHCl3); 
1H-NMR (300 MHz, CDCl3): δ 7.39-7.25 (m, 20H, Ar), 5.18 (bt, 1H, NH), 
5.09 (m, 3H, H-1A, CH2(Z)), 5.05 (d, 1H, J1,2 = 3.6 Hz, H-1B), 4.95 (t, 1H, J1,2 = J2,3 = 
4.8 Hz, H-2A), 4.85 (d, 1H, CH2(OBn)), 4.83 (bs, 2H, CH2(OBn)), 4.75 (m, 2H, 
CH2(OBn)), 4.72 (d, 1H, J4,5 = 4.4 Hz, H-5A), 4.59 (d, 1H, CH2(OBn)), 4.32 (dd, 1H, 
J5,6a = 1.9 Hz, J6a,6b = 12.1 Hz, H-6aB), 4.18 (dd, 1H, J5,6b = 4.2 Hz, H-6bB), 4.14 (t,1H, 
J3,4 = 4.5 Hz, H-4A), 3.98 (t, 1H, H-3A), 3.94 (m, 1H, H-5B), 3.87 (dd, 1H, J2,3 = 10.3 
Hz, J3,4 = 8.9 Hz, H-3B), 3.81 (m, 1H, CH2-O), 3.78 (s, 3H, COOMe), 3.63 (m, 1H, 
CH2-O), 3.52 (dd, 1H, J4,5 = 9.9 Hz, H-4B), 3.40 (m, 2H, CH2-N), 3.28 (dd, 1H, H-2B), 
2.01 (s, 3H, CH3(Ac)), 1.20 (s, 9H, (CH3)3(Piv)); 
13C-NMR (125 MHz, CDCl3): δ 
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177.6, 170.6, 169.7 (CO(Ac, Piv, COOMe)), 156.5 (CO(Z)), 137.8-136.6 (Ar-C), 128.7-
127.6 (Ar-CH), 99.2 (C-1A), 98.3 (C-1B), 80.0 (C-3B), 77.8 (C-4B), 75.8 (C-3A), 75.5, 
74.9 (CH2(OBn)), 73.8 (C-4A), 73.4 (CH2(OBn)), 70.4, 70.1 (C-2A, C-5A, C-5B), 68.5 
(CH2-O), 66.8 (CH2(Z)), 63.4 (C-2B), 62.6 (C-6B), 52.5 (COOMe), 40.9 (CH2-N), 38.9 
(C(Piv)), 27.2 ((CH3)3(Piv)), 20.9 (CH3(Ac)); HR MS: m/z: calcd for C51H60N4O15Na: 
991.3953; found: 991.3984 [M+Na]+. 
Methyl 4-O-(6-O-acetyl-2-azido-3,4-di-O-benzyl-2-deoxy-α-D-glucopyranosyl)-3-O-
benzyl-2-O-pivaloyl-α,β-L-idopyranosuronate (17): TMSOTf (22 µL of a 0.18 M 
solution in dry CH2Cl2) was added to a cooled (0ºC) solution of 2 (1.21 g, 2.75 mmol) 
in dry CH2Cl2 (30 mL) under an argon atmosphere. While the reaction was stirred, a 
solution of 16 (1.31 g, 2.29 mmol) in dry CH2Cl2 (10 mL) was added dropwise. After 
20 min at 0ºC, the mixture was neutralized with Et3N and concentrated in vacuo. The 
residue was separated by flash column chromatography (toluene/EtOAc 12:1) to obtain 
the desired α (1→4) disaccharide. This compound was dissolved in Py (15 mL). 
Pivaloyl chloride (5 mL) and DMAP (cat.) were added and the solution was stirred at 
room temperature. After 24 h, the mixture was diluted with CH2Cl2, washed with 1 M 
HCl aqueous solution, saturated NaHCO3 aqueous solution and H2O, dried (MgSO4), 
filtered, and concentrated in vacuo. The residue was purified by flash column 
chromatography (toluene/EtOAc 49:1) to yield the desired 2-O-pivaloylated 
disaccharide (1.1 g, 47%, 2 steps). TLC (toluene-EtOAc 12:1) Rf 0.43; 
1H-NMR (500 
MHz, CDCl3): δ 7.39-7.25 (m, 15H, Ar), 5.04 (bs, 2H, H-1A, H-2A), 4.94 (d, 1H, J1,2 = 
3.5 Hz, H-1B), 4.85-4.58 (m, 6H, CH2(OBn)), 4.42 (bd, 1H, H-5A), 4.35 (dd, 1H, J5,6a = 
1.9 Hz, J6a,6b = 12.3 Hz, H-6aB), 4.20 (dd, 1H, J5,6b = 2.8 Hz, H-6bB), 4.09-4.04 (m, 2H, 
H-5B, H-4A), 4.01-3.97 (m, 2H, H-3A, H-3B), 3.74 (s, 3H, COOMe), 3.57 (t, 1H, J4,5 = 
9.5 Hz, H-4B), 3.28 (dd, 1H, J2,3 = 10.3 Hz, H-2B), 2.00 (s, 3H, CH3(Ac)), 1.63 (hp, 1H, 
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CH(CH3)2), 1.27 (s, 9H, C(CH3)3), 0.88-0.85 (12H, CH(CH3)2, C(CH3)2), 0.20, 0.15 (2s, 
6H, Si(CH3)2); 
13C-NMR (125 MHz, CDCl3) (Significant data from HMQC 
experiment): δ 98.8 (C-1B), 94.5 (C-1A), 80.2 (C-3B), 77.5 (C-4B), 75.6 (C-3A), 75.4 
(CH2(OBn)), 74.7 (CH2(OBn)), 74.4 (C-4A), 73.4 (C-5A), 73.0 (CH2(OBn)), 69.8 
(C-5B), 67.7 (C-2A), 63.5 (C-2B), 62.3 (C-6B), 52.0 (COOMe); ESI MS: m/z: calcd for 
C49H67N3O13SiNa: 956.4; found: 956.0 [M+Na]
+. 
To a solution of this 2-O-pivaloylated disaccharide (0.8 g, 0.86 mmol) at –15°C 
in dry THF (23 mL), an excess of (HF)n·Py (2.4 mL) was added. The reaction was 
warmed to 0°C and stirred for 28 h under an argon atmosphere. Then, the reaction was 
stirred at room temperature until complete disappearance of starting material. The 
mixture was diluted with CH2Cl2 and washed with H2O and saturated NaHCO3 solution 
until neutral pH. The organic layer was dried (MgSO4), filtered, and concentrated in 
vacuo to give 17 (615 mg, 91%). TLC (hexane-EtOAc 2:1) Rf 0.29; 
1H-NMR (300 
MHz, CDCl3) (data for major anomer): δ 7.37-7.25 (m, 15H, Ar), 5.38 (bd, 1H, J1,2 = 
4.8 Hz, H-1A), 5.06 (d, 1H, J1,2 = 3.6 Hz, H-1B), 4.89-4.78 (m, 7H, H-2A, H-5A, 
CH2(OBn)),4.6 (m, 1H, CH2(OBn)), 4.33 (dd, 1H, J5,6a = 2.1 Hz, J6a,6b = 12.0 Hz, 
H-6aB), 4.21-4.10 (m, 3H, H-6bB, H-3A, H-4A), 3.95 (ddd, 1H, J4,5 = 10.0 Hz, J5,6b = 
4.1 Hz,H-5B), 3.85 (dd, 1H, J2,3 = 10.2 Hz,  J3,4 = 8.8 Hz, H-3B), 3.80 (s, 3H, COOMe), 
3.51 (dd, 1H, H-4B), 3.30 (dd, 1H, H-2B), 2.02 (s, 3H, CH3(Ac)), 1.24 (s, 9H, 
(CH3)3(Piv)); 
13C-NMR (75 MHz, CDCl3) (selected data for major anomer from HMQC 
experiment): δ 99.0 (C-1B), 93.6 (C-1A), 80.0 (C-3B), 77.7 (C-4B), 75.4, 74.1 (C-3A, 
C-4A), 70.1 (C-5A), 70.0 (C-5B), 63.3 (C-2B), 62.4 (C-6B), 52.4 (COOMe), 27.2 
((CH3)3(Piv)), 20.8 (CH3(Ac)); 
1H-NMR (300 MHz, CDCl3) (selected data for minor 
anomer): δ 7.37-7.25 (m, 15H, Ar), 5.23 (bd, 1H, H-1A), 4.99 (d, 1H, J1,2=3.6 Hz, 
H-1B), 4.94-4.57 (m, 8H, H-2A, H-5A, CH2(OBn)), 3.80 (s, 3H, COOMe), 3.34 (dd, 
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1H, H-2B), 2.02 (s, 3H, CH3(Ac)), 1.24 (s, 9H, (CH3)3(Piv)); HR MS: m/z: calcd for 
C41H49N3O13Na: 814.3163; found: 814.3159 [M+Na]
+. 
O-(Methyl 4-O-(6-O-acetyl-2-azido-3,4-di-O-benzyl-2-deoxy-α-D-glucopyranosyl)-
3-O-benzyl-2-O-pivaloyl-α,β-L-idopyranosyluronate) trichloroacetimidate (18): 
K2CO3 (13 mg, 96 µmol) and trichloroacetonitrile (119 µL, 1.19 mmol) were added at 
room temperature to a solution of 17 (63 mg, 80 µmol) in dry CH2Cl2 (1 mL). After 
stirring for 6 h at room temperature, the reaction mixture was filtered through a pad of 
Celite and concentrated to dryness. The residue was purified by column 
chromatography (hexane-EtOAc 3:1 + 1% Et3N) to yield 18 (70 mg, 94%). TLC 
(hexane-EtOAc 2:1) Rf 0.49, 0.59 (α and β anomers); 1H-NMR (300 MHz, CDCl3) (for 
major anomer): δ 8.71 (s, 1H, NH), 7.36-7.25 (m, 15H, Ar), 6.44 (d, 1H,  J1,2 = 2.7 Hz,  
H-1A), 5.20 (t, 1H, J2,3 = 3.3 Hz, H-2A), 5.03 (d, 1H, J1,2 = 3.5 Hz, H-1B), 4.91 (d, 1H, 
J4,5 = 3.2 Hz, H-5A), 4.87-4.58 (m, 6H, CH2(OBn)), 4.35 (dd, 1H, J5,6a = 2.0 Hz, J6a,6b = 
12.1 Hz, H-6aB), 4.23 (t, 1H, J3,4 = 3.8 Hz, H-4A), 4.18 (dd, 1H, J5,6b = 3.7 Hz, H-6bB), 
4.07 (t, 1H, H-3A), 3.95 (ddd, 1H, H-5B), 3.90 (dd, 1H, J2,3 = 10.3 Hz, J3,4 = 8.8 Hz, 
H-3B), 3.80 (s, 3H, COOMe), 3.54 (dd, 1H, J4,5 = 9.9 Hz, H-4B), 3.33 (dd, 1H, H-2B), 
2.01 (s, 3H, CH3(Ac)), 1.26 (s, 9H, (CH3)3(Piv)); 
13C-NMR (75 MHz, CDCl3) (selected 
data for major anomer from HSQC experiment): δ 98.4 (C-1B), 95.5 (C-1A), 80.1 
(C-3B), 77.5 (C-4B), 75.3, 74.8 (CH2(OBn)), 74.2 (C-3A), 73.7 (C-4A), 72.8 
(CH2(OBn)), 70.1 (C-5A, C-5B), 67.6 (C-2A), 63.3 (C-2B), 62.4 (C-6B), 52.4 
(COOMe), 27.1 ((CH3)3(Piv)), 20.7 (CH3(Ac)); 
1H-NMR (300 MHz, CDCl3) (selected 
data for minor anomer): δ 8.64 (s, 1H, NH), 7.36-7.25 (m, 15H, Ar), 6.38 (d, 1H,  J1,2 = 
2.7 Hz,  H-1A), 5.21 (m, 1H, H-2A), 5.00 (d, 1H, J1,2 = 3.9 Hz, H-1B), 4.87-4.58 (m, 
7H, CH2(OBn), H-5A (4.66)), 4.40-4.29 (m, 2H, H-3A, H-6aB), 4.25-4.04 (m, 2H, H-
6bB, H-4A), 3.99-3.82 (m, 2H, H-3B, H-5B), 3.78 (s, 3H, COOMe), 3.52 (m, 1H, H-
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4B), 3.38 (dd, 1H, J2,3 = 10.3 Hz, H-2B), 2.01 (s, 3H, CH3(Ac)), 1.26 (s, 9H, 
(CH3)3(Piv)); 
13C-NMR (75 MHz, CDCl3) (selected data for minor anomer from HSQC 
experiment): δ 99.3 (C-1B), 94.8 (C-1A), 80.1 (C-3B), 77.5 (C-4B), 76.1 (C-4A), 74.6 
(C-3A), 70.1 (C-5B), 68.5 (C-2A), 63.6 (C-2B), 52.4 (COOMe), 27.1 ((CH3)3(Piv)), 
20.7 (CH3(Ac)); ESI MS: m/z: calcd for C43H49Cl3N4O13Na: 957.2; found: 956.7 
[M+Na]+. 
N-Benzyloxycarbonyl-2-aminoethyl O-(6-O-acetyl-2-azido-3,4-di-O-benzyl- 
2-deoxy-α-D-glucopyranosyl)-(1→4)-O-(methyl 3-O-benzyl-2-O-pivaloyl-α-L-
idopyranosyluronate)-(1→4)-O-(6-O-acetyl-2-azido-3-O-benzyl-2-deoxy-α-D-
glucopyranosyl)-(1→4)-methyl 3-O-benzyl-2-O-pivaloyl-α-L-idopyranosiduronate 
(19): TMSOTf (127 µL of a 0.18 M solution in dry CH2Cl2) was added under an argon 
atmosphere at 0ºC to a mixture of 9 (44 mg, 0.05 mmol) and 18 (70 mg, 0.075 mmol) in 
dry CH2Cl2 (1.0 mL). After stirring for 20 min at 0ºC, the reaction mixture was 
neutralized with Et3N and concentrated to dryness. The residue was purified by column 
chromatography (toluene-EtOAc 5:1) to afford 19 (40 mg, 48%) and unreacted 9 (20 
mg, 45%). TLC (hexane-EtOAc 2:1) Rf 0.26; [α]
20
D  +10º (c 1.2, CHCl3); 
1H-NMR (500 
MHz, CDCl3): δ 7.37-7.23 (m, 30H, Ar), 5.31 (d, 1H, J1,2 = 5.2 Hz, H-1C), 5.16 (bt, 1H, 
NH), 5.11 (d, 1H, J1,2 = 4.7 Hz, H-1A), 5.09 (bs, 2H, CH2(Z)), 5.05 (d, 1H, J1,2 = 3.5 Hz, 
H-1D), 5.02 (d, 1H, J1,2 = 3.5 Hz, H-1B), 4.99 (t, 1H, J2,3 = 5.6 Hz, H-2C), 4.96-4.92 (m, 
2H, H-2A, CH2(OBn)), 4.86-4.68 (m, 8H, CH2(OBn)), 4.67 (d, 1H, J4,5 = 4.6 Hz, 
H-5A), 4.62 (d, 1H, J4,5 = 5.0 Hz, H-5C), 4.59 (d, 1H, CH2(OBn)), 4.36-4.29 (m, 2H, 
H-6aB, H-6bB), 4.26 (dd, 1H, J5,6a = 1.8 Hz, J6a,6b = 12.2 Hz, H-6aD), 4.16 (dd, 1H, J5,6b 
= 3.4 Hz, H-6bD), 4.11 (t, 1H, J3,4 = 5.2 Hz, H-4A), 4.08 (t, 1H, J3,4 = 5.3 Hz, H-4C), 
3.97-3.90 (m, 5H, H-3A, H-3C, H-4B, H-5B, H-5D), 3.84-3.80 (m, 2H, H-3D, CH2-O), 
3.75-3.70 (m, 4H, H-3B, COOMe), 3.64-3.58 (m, 4H, COOMe, CH2-O), 3.54 (t, 1H, 
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J3,4 = J4,5 = 9.3 Hz, H-4D), 3.39 (m, 2H, CH2-N), 3.29 (m, 2H, H-2D, H-2B), 2.10, 1.96 
(2s, 6H, CH3(Ac)), 1.21, 1.19 (2s, 18H, (CH3)3(Piv)); 
13C-NMR (125 MHz, CDCl3) 
(Significant data from HSQC experiment): δ 99.0 (C-1A), 98.4 (C-1D), 97.9 (C-1B), 
97.8 (C-1C), 79.9 (C-3D), 77.9 (C-3B), 77.4 (C-4D), 75.9 (C-3C, C-3A), 75.3, 75.0 
(CH2(OBn)), 74.9 (C-4B), 74.7, 73.8 (CH2(OBn)), 73.7 (C-4C, C-4A), 73.3 
(CH2(OBn)), 70.8 (C-2C), 70.7 (C-5C), 70.2 (C-2A), 70.1 (C-5A), 69.9 (C-5B), 69.7 
(C-5D), 68.2 (CH2-O), 66.6 (CH2(Z)), 63.0 (C-2B, C-2D), 62.3 (C-6D), 61.9 (C-6B), 
52.2, 51.9 (COOMe), 40.8 (CH2-N), 27.1 ((CH3)3(Piv)), 20.7 (CH3(Ac)); HR MS: m/z: 
calcd for C85H101N7O27Na: 1674.6643; found: 1674.6697 [M+Na]
+. 
N-Benzyloxycarbonyl-2-aminoethyl O-(6-O-acetyl-2-azido-3,4-di-O-benzyl- 
2-deoxy-α-D-glucopyranosyl)-(1→4)-O-(methyl 3-O-benzyl-2-O-pivaloyl-α-L-
idopyranosyluronate)-(1→4)-O-(6-O-acetyl-2-azido-3-O-benzyl-2-deoxy-α-D-
glucopyranosyl)-(1→4)-O-(methyl 3-O-benzyl-2-O-pivaloyl-α-L-
idopyranosyluronate)-(1→4)-O-(6-O-acetyl-2-azido-3-O-benzyl-2-deoxy-α-D-
glucopyranosyl)-(1→4)-methyl 3-O-benzyl-2-O-pivaloyl-α-L-idopyranosiduronate 
(20): BF3·Et2O (145 µL of a 0.2 M solution in dry CH2Cl2) was added under an argon 
atmosphere at room temperature to a mixture of 12 (30 mg, 19 µmol) and 18 (29 mg, 31 
µmol) in dry CH2Cl2 (1.0 mL). After stirring for 30 min, the reaction mixture was 
neutralized with Et3N and concentrated to dryness. The residue was purified by column 
chromatography (toluene-EtOAc 5:1→1:1) to afford 20 (23 mg, 52%), and unreacted 12 
(8 mg, 27%). TLC (toluene-EtOAc 4:1) Rf 0.38; [α]
20
D  +4º (c 1.1, CHCl3); 
1H-NMR 
(500 MHz, CDCl3): δ 7.39-7.25 (m, 40H, Ar), 5.37 (d, 1H, J1,2 = 6.0 Hz, H-1E), 5.31 (d, 
1H, J1,2 = 5.4 Hz, H-1C), 5.15 (bt, 1H, NH), 5.12 (d, 1H, J1,2 = 4.8 Hz, H-1A), 5.09 (bs, 
2H, CH2(Z)), 5.06-4.97 (m, 5H, H-1B, H-1D, H-1F, H-2C, H-2E), 4.96-4.90 (m, 3H, 
H-2A, CH2(OBn)), 4.87-4.67 (m, 11H, CH2(OBn)), 4.65 (d, 1H, J4,5 = 4.6 Hz, H-5A), 
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4.61-4.56 (m, 2H, H-5C, CH2(OBn)), 4.49 (d, 1H, J4,5 = 5.6 Hz, H-5E), 4.34-4.24 (m, 
5H, H-6aB, H-6bB, H-6aD, H-6bD, H-6aF), 4.15 (dd, 1H, J5,6 = 3.3 Hz, J6a,6b = 12.2 Hz, 
H-6bF), 4.11 (t, 1H, J3,4 = 5.3 Hz, H-4A), 4.08 (t, 1H, J3,4 = 5.7 Hz, H-4C), 4.03 (t, 1H, 
J3,4 = 6.2 Hz, H-4E), 3.97-3.86 (m, 8H, H-3A, H-3C, H-3E, H-4B, H-4D, H-5B, H-5D, 
H-5F), 3.84-3.78 (m, 2H, H-3F, CH2-O), 3.75-3.69 (m, 4H, H-3B or H-3D, COOMe), 
3.66-3.58 (m, 8H, H-3B or H-3D, COOMe (3.64, 3.61), CH2-O), 3.53 (t, 1H, J3,4 = J4,5 = 
9.4 Hz, H-4F), 3.39 (m, 2H, CH2-N), 3.32-3.27 (m, 3H, H-2B, H-2D, H-2F), 2.11, 2.07, 
1.96 (3s, 9H, CH3(Ac)), 1.19 (bs, 27H, (CH3)3(Piv)); 
13C-NMR (125 MHz, CDCl3) 
(Significant data from HSQC experiment): δ 99.0 (C-1A), 98.1 (C-1B, C-1D, C-1F), 
97.7 (C-1C), 97.5 (C-1E), 80.0 (C-3F), 79.9, 77.7 (C-3B, C-3D), 77.4 (C-4F), 76.8-73.5 
(C-3A, C-3C, C-3E, C-4B, C-4D, C-4A, C-4C, C-4E, CH2(OBn)), 71.5 (C-2E, C-5E), 
71.0 (C-2C, C-5C), 70.4 (C-2A), 70.3 (C-5A), 69.8 (C-5B, C-5D, C-5F), 68.4 (CH2-O), 
66.7 (CH2(Z)), 62.9 (C-2B, C-2D, C-2F), 62.2 (C-6F), 61.8 (C-6B, C-6D), 52.3-52.0 
(COOMe), 40.9 (CH2-N), 27.0 ((CH3)3(Piv)), 20.8 (CH3(Ac)); ESI MS: m/z: calcd for 
C119H142N10O39Na: 2357.9; found: 2357.7 [M+Na]
+.  
2-aminoethyl 4-O-(2-deoxy-2-sulfamido-6-O-sulfo-α-D-glucopyranosyl)-2-O-sulfo-
α-L-idopyranosiduronic acid (21): H2O2 (30%, 1.8 mL) and a solution of LiOH (0.7 
M, 1.1 mL) were added at -5ºC to a solution of 15 (43 mg, 44 µmol) in THF (4.3 mL). 
After stirring for 20 h at room temperature, MeOH (4.3 mL) and an aqueous solution of 
NaOH (4 M, 1.1 mL) were added. After stirring for 20-24 h at room temperature, the 
reaction mixture was neutralized with a 4 M solution of HCl and then diluted with 
CH2Cl2 (40 mL) and washed with H2O (20 mL). The organic phase was extracted with a 
solution of Na2SO3 (10%), dried (MgSO4), filtered, and concentrated to give N-
benzyloxycarbonyl-2-aminoethyl 4-O-(2-azido-3,4-di-O-benzyl-2-deoxy-α-D-
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glucopyranosyl)-3-O-benzyl-α-L-idopyranosiduronic acid (30 mg, 82%). ESI MS: m/z: 
calcd for C43H47N4O13: 827.3; found: 826.8 [M-H]
-. 
This compound (12 mg, 14 µmol), sulfur trioxide–trimethylamine complex (20 mg, 145 
µmol) and a magnetic stirrer bar were placed in a 5 mL microwave reaction vial and 
fitted with a septum, which was then pierced with a needle. The closed vial was then 
evacuated under high vacuum and left to dry for 12 h. Argon was let in, dry DMF (1.0 
mL) was added and the reaction mixture was subjected to microwave radiation for 15 
min at 100ºC (80 W average power). The reaction vessel was cooled under a stream of 
nitrogen and quenched with Et3N (200 µL). MeOH (1 mL) and CH2Cl2 (1 mL) were 
added, and the solution was layered on the top of a Sephadex LH-20 chromatography 
column which was eluted with CH2Cl2/MeOH (1:1) to obtain N-benzyloxycarbonyl-2-
aminoethyl 4-O-(2-azido-3,4-di-O-benzyl-2-deoxy-6-O-sulfo-α-D-glucopyranosyl)-3-O-
benzyl-2-O-sulfo-α-L-idopyranosiduronic acid as triethylammonium salt (17 mg, 91%). 
TLC (EtOAc-Py-H2O-AcOH 10:5:3:1) Rf 0.51; 
1H-NMR (500 MHz, MeOD): δ 7.43-
7.25 (m, 20 H, Ar), 5.18 (bs, 1H, H-1A), 5.06 (m, 3H, H-1B, CH2(Z)), 4.90-4.65 (m, 
7H, H-5A (4.74), CH2(OBn)), 4.49 (bs, 1H, H-2A), 4.33 (dd, 1H, J5,6a = 2.8 Hz, J6a,6b = 
10.7 Hz, H-6aB), 4.25 (bt, 1H, H-3A), 4.20 (dd, 1H, J5,6b = 1.9 Hz, H-6bB), 4.14 (bt, 
1H, H-4A), 3.97-3.93 (m, 2H, H-5B, H-3B), 3.80 (m, 1H, CH2-O), 3.66 (t, 1H, J3,4 = J4,5 
= 9.4 Hz, H-4B), 3.59 (m, 1H, CH2-O), 3.32 (m, 3H, H-2B, CH2-N), 3.19 (q, Et3NH
+), 
1.32 (t, Et3NH
+); 13C-NMR (125 MHz, MeOD) (Significant data from HSQC 
experiment): δ 99.4 (C-1A), 96.5 (C-1B), 79.7 (C-3B), 77.6 (C-4B), 72.8 (C-3A), 71.9 
(C-4A), 71.7 (C-2A), 70.2(C-5B), 67.1 (C-5A), 66.8 (CH2-O), 65.5 (C-6B), 63.4 
(C-2B); ESI MS: m/z: calcd for C43H47N4O19S2: 987.2; found: 986.7 [M+2H]
-; calcd for 
C61H94N7O19S2: 1292.6; found: 1292.1 [M+3Et3NH+H]
+. 
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This compound (45 mg, 35 µmol) was dissolved in THF (4.5 mL) and treated 
with a 0.1 M aqueous solution of NaOH (1.5 mL). Then, a solution of Me3P in THF 
(139 µL of a 1 M solution) was added and the reaction was stirred for 3 h. The reaction 
mixture was neutralized with a 0.1 M solution of HCl and concentrated to afford N-
benzyloxycarbonyl-2-aminoethyl 4-O-(2-amino-3,4-di-O-benzyl-2-deoxy-6-O-sulfo-α-
D-glucopyranosyl)-3-O-benzyl-2-O-sulfo-α-L-idopyranosiduronic acid as sodium salt. 
TLC (EtOAc-Py-H2O-AcOH 10:5:3:1) Rf 0.61; ESI MS: m/z: calcd for 
C43H48N2O19S2Na: 983.2; found: 982.7 [M+Na+H]
-; calcd for C43H48N2O19S2: 480.1; 
found: 479.7 [M+H]2-; calcd for C43H49N2O19S2: 961.2; found: 960.7 [M+2H]
-. 
Triethylamine (0.68 mL) and then sulfur trioxide-pyridine complex (56 mg, 350 
µmol) were added to a solution of this disaccharide (35 µmol) in anhydrous pyridine 
(3.0 mL). After stirring for 4 h at room temperature under an argon atmosphere, the 
reaction mixture was purified by Sephadex LH-20 chromatography (CH2Cl2/MeOH 1:1) 
and RP-18 chromatography (10 mM AcOH-Et3N (pH 7.0)/MeOH 70:30→30:70) to give  
N-benzyloxycarbonyl-2-aminoethyl 4-O-(3,4-di-O-benzyl-2-deoxy-2-sulfamido-6-O-
sulfo-α-D-glucopyranosyl)-3-O-benzyl-2-O-sulfo-α-L-idopyranosiduronic acid as 
triethylammonium salt. The corresponding sodium salt was obtained by elution from a 
column of Dowex 50WX4-Na+ with MeOH/H2O 9:1. TLC (EtOAc-Py-H2O-AcOH 
10:5:3:1) Rf 0.29; 
1H-NMR (500 MHz, MeOD) (data for triethylammonium salt): δ 
7.46-7.21 (m, 20H, Ar), 5.45 (d, 1H, J1,2 = 3.2 Hz, H-1B), 5.22 (bs, 1H, H-1A), 5.14 (d, 
1H, CH2(OBn)), 5.03 (m, 2H, CH2(Z)), 4.88-4.73 (m, 6H, H-5A (4.74), CH2(OBn)), 
4.55 (m, 2H, H-2A, H-3A), 4.36 (dd, 1H, J5,6a = 2.1 Hz, J6a,6b = 10.7 Hz, H-6aB), 4.24 
(dd, 1H, J5,6b = 1.8 Hz, H-6bB), 4.21 (bs, 1H, H-4A), 3.92 (bd, 1H, H-5B), 3.80 (dd, 1H, 
J2,3 = 10.4 Hz, J3,4 = 9.4 Hz, H-3B), 3.76 (m, 1H, CH2-O), 3.62 (t, 1H, J4,5 = 9.4 Hz, H-
4B), 3.55 (m, 1H, CH2-O), 3.44 (dd, 1H, H-2B), 3.35 (m, 2H, CH2-N), 3.19 (q, 
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Et3NH
+), 1.30 (t, Et3NH
+); 13C-NMR (125 MHz, MeOD) (Significant data from HSQC 
experiment): δ 102.1 (C-1B), 100.5 (C-1A), 81.2 (C-3B), 78.5 (C-4B), 78.0 (C-4A), 
76.1 (C-3A, CH2(OBn)), 75.7 (CH2(OBn)), 73.0 (CH2(OBn)), 72.6 (C-2A), 71.1 (C-
5B), 67.9 (CH2-O), 67.7 (C-5A), 67.2 (CH2(Z)), 67.0 (C-6B), 60.3 (C-2B); ESI MS: 
m/z: calcd for C43H46N2O22S3NaK: 550.1; found: 550.7 [M+Na+K]
2-. 
A solution of this compound (35 µmol, as sodium salt) in H2O/MeOH (2.7 
mL/0.3 mL) was hydrogenated in the presence of Pd(OH)2. After 24 h, the suspension 
was filtered over Celite and concentrated. The residue was purified by Sephadex G-25 
chromatography (H2O/MeOH 9:1) to give 21 after lyophilisation (15.3 mg, 60% from 
N-benzyloxycarbonyl-2-aminoethyl 4-O-(2-azido-3,4-di-O-benzyl-2-deoxy-6-O-sulfo-
α-D-glucopyranosyl)-3-O-benzyl-2-O-sulfo-α-L-idopyranosiduronic acid, 3 steps; 45% 
from 15, 5 steps, 85% average yield per step). 1H-NMR (500 MHz, D2O): δ 5.46 (d, 1H, 
J1,2 = 3.5 Hz, H-1B), 5.15 (d, 1H, J1,2 = 3.4 Hz, H-1A), 4.55 (d, 1H, J4,5 = 2.9 Hz, H-5A), 
4.36 (dd, 1H, J5,6a = 3.1 Hz, J6a,6b = 11.2 Hz, H-6aB), 4.33 (dd, 1H, J2,3 = 6.5 Hz,  H-2A), 
4.23 (m, 2H, H-3A, H-6bB), 4.14 (t, 1H, J3,4 = 3.3 Hz, H-4A), 4.04 (m, 1H, CH2-O), 
4.00 (dt, 1H, J4,5 = 9.8 Hz, H-5B), 3.82 (m, 1H, CH2-O), 3.64 (t, 1H, J2,3 = J3,4 = 9.7 Hz, 
H-3B), 3.57 (t, 1H, J4,5 = 9.7 Hz, H-4B), 3.26 (m, 3H, H-2B, CH2-N); 
13C-NMR (125 
MHz, D2O) (Significant data from HMQC experiment): δ 99.3 (C-1A), 96.4 (C-1B), 
76.7 (C-2A), 75.7 (C-4A), 70.8 (C-3B), 69.7 (C-5B), 69.3 (C-5A), 69.2 (C-3A), 69.1 
(C-4B), 66.5 (C-6B), 64.1 (CH2-O), 57.7 (C-2B), 39.2 (CH2-N); ESI MS: m/z: calcd for 
C14H23N2O20S3Na2: 680.98; found: 680.97 [M+H+2Na]
-; calcd for C14H24N2O20S3Na: 
659.00; found: 658.99 [M+2H+Na]-; calcd for C14H25N2O20S3: 637.01; found: 637.01 
[M+3H]-. 
2-aminoethyl O-(2-deoxy-2-sulfamido-6-O-sulfo-α-D-glucopyranosyl)-(1→4)-O-(2-
O-sulfo-α-L-idopyranosyluronic acid)-(1→4)-O-(2-deoxy-2-sulfamido-6-O-sulfo-α-
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D-glucopyranosyl)-(1→4)-2-O-sulfo-α-L-idopyranosiduronic acid (22): H2O2 (30%, 
0.44 mL) and a solution of LiOH (0.7 M, 0.27 mL) were added at -5ºC to a solution of 
19 (18 mg, 11 µmol) in THF (1.2 mL). After stirring for 20 h at room temperature, 
MeOH (1.2 mL) and a solution of NaOH (4 M, 0.28 mL) were added. After stirring for 
20-24 h at room temperature, the reaction mixture was neutralized with a 4 M solution 
of HCl and then diluted with CH2Cl2 (20 mL) and washed with H2O (10 mL). The 
organic phase was extracted with a solution of Na2SO3 (10%), dried (MgSO4), filtered, 
and concentrated to give N-benzyloxycarbonyl-2-aminoethyl O-(2-azido-3,4-di-O-
benzyl- 
2-deoxy-α-D-glucopyranosyl)-(1→4)-O-(3-O-benzyl-α-L-idopyranosyluronic acid)-
(1→4)-O-(2-azido-3-O-benzyl-2-deoxy-α-D-glucopyranosyl)-(1→4)-3-O-benzyl-α-L-
idopyranosiduronic acid (12 mg, 80%). ESI MS: m/z: calcd for C69H76N7O23: 1370.5; 
found: 1369.9 [M-H]-; calcd for C69H74N7O23Na4: 1460.4; found: 1459.8 [M-3H+4Na]
+. 
This compound (12 mg, 8.7 µmol) and sulfur trioxide–trimethylamine complex (24 mg, 
174 µmol) were dissolved in dry DMF (1.0 mL) and heated at 100ºC for 30 min using 
microwave radiation as described above. The reaction vessel was cooled and Et3N (150 
µL), MeOH (1 mL) and CH2Cl2 (1 mL) were added. The solution was layered on the 
top of a Sephadex LH-20 chromatography column which was eluted with 
CH2Cl2/MeOH (1:1) to obtain N-benzyloxycarbonyl-2-aminoethyl O-(2-azido-3,4-di-O-
benzyl-2-deoxy-6-O-sulfo-α-D-glucopyranosyl)-(1→4)-O-(3-O-benzyl-2-O-sulfo-α-L-
idopyranosyluronic acid)-(1→4)-O-(2-azido-3-O-benzyl-2-deoxy-6-O-sulfo-α-D-
glucopyranosyl)-(1→4)-3-O-benzyl-2-O-sulfo-α-L-idopyranosiduronic acid as 
triethylammonium salt (19 mg, 95%). The corresponding sodium salt was obtained by 
elution from a column of Dowex 50WX4-Na+ with MeOH/H2O 3:1. TLC (EtOAc-Py-
H2O-AcOH 10:5:3:1) Rf 0.44;
 1H-NMR (500 MHz, MeOD): δ 7.46-7.17 (m, 30H, Ar), 
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5.49 (bs, 1H, H-1C), 5.22 (bs, 1H, H-1A), 5.10 (d, 1H, J1,2 = 3.7 Hz, H-1B), 5.06 (bs, 
2H, CH2(Z)), 5.01 (d, 1H, J1,2 = 3.7 Hz, H-1D), 5.00 (d, 1H, J4,5 = 1.5 Hz, H-5C), 4.90-
4.64 (m, 10H, CH2(OBn), H-5A (4.83)), 4.60 (bs, 1H, H-2C), 4.52 (bs, 1H, H-2A), 4.42 
(d, 1H, CH2(OBn)), 4.35-4.31 (m, 2H, H-6aB, H-6aD), 4.27-4.22 (m, 3H, H-3A, H-3C, 
H-6bB), 4.16 (bs, 1H, H-4A), 4.12 (bd, 1H, H-6bD), 4.05 (t, 1H, J3,4 = J4,5 = 9.6 Hz, 
H-4B), 3.97 (m, 2H, H-4C, H-5B), 3.85 (m, 2H, H-3D, CH2-O), 3.74 (m, 2H, H-3B, 
H-5D), 3.67-3.60 (m, 2H, H-4D, CH2-O), 3.47 (dd, 1H, J2,3 = 10.3 Hz, H-2D), 3.37 (m, 
2H, CH2-N), 3.29 (dd, 1H, J2,3 = 10.3 Hz, H-2B);
 13C-NMR (125 MHz, MeOD) 
(Significant data from HSQC experiment): δ 100.6 (C-1A), 98.2 (C-1C), 96.6 (C-1D), 
96.3 (C-1B), 81.5 (C-3D), 79.6 (C-3B), 78.5 (C-4D), 76.2, 76.1, 75.6, 73.1, 73.1 
(CH2(OBn)), 72.4 (C-3A), 72.1 (C-2A, C-4B), 72.0 (C-4C), 71.7 (C-3C, C-4A), 71.3 
(C-5B), 71.2 (C-5D), 70.7 (C-2C), 68.2 (CH2-O), 67.8 (C-5A), 67.3 (C-5C), 67.2 
(CH2(Z)), 67.1 (C-6B), 66.6 (C-6D), 65.3 (C-2B), 65.0 (C-2D), 41.4 (CH2-N); ESI MS: 
m/z: calcd for C69H73N7O35S4K2: 882.6; found: 882.4 [M+2H+2K]
2-; calcd for 
C75H90N8O35S4: 895.2; found: 894.9 [M+3H+Et3NH]
2-; calcd for C69H71N7O35S4K2Na2: 
904.6; found: 904.9 [M+2K+2Na]2-. 
This compound (9 mg, 5 µmol) was dissolved in THF (1.6 mL) and treated with 
a 0.1 M aqueous solution of NaOH (0.43 mL). Then, a solution of Me3P in THF (40 µL 
of a 1 M solution) was added and the reaction was stirred for 3 h. The reaction mixture 
was neutralized with a 0.1 M solution of HCl and concentrated to afford N-
benzyloxycarbonyl-2-aminoethyl O-(2-amino-3,4-di-O-benzyl-2-deoxy-6-O-sulfo-α-D-
glucopyranosyl)-(1→4)-O-(3-O-benzyl-2-O-sulfo-α-L-idopyranosyluronic acid)-(1→4)-
O-(2-amino-3-O-benzyl-2-deoxy-6-O-sulfo-α-D-glucopyranosyl)-(1→4)-3-O-benzyl-2-
O-sulfo-α-L-idopyranosiduronic acid as sodium salt. TLC (EtOAc-Py-H2O-AcOH 
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10:5:3:1) Rf 0.43; ESI MS: m/z: calcd for C69H79N3O35S4: 818.7; found: 818.1 [M+4H]
2-
; calcd for C69H75N3O35S4Na4: 862.6; found: 862.0 [M+4Na]
2-. 
Triethylamine (110 µL) and then sulfur trioxide-pyridine complex (16 mg, 98 
µmol) were added to a solution of this compound (5 µmol) in anhydrous pyridine (0.6 
mL). After stirring for 6 h at room temperature under an argon atmosphere, the reaction 
mixture was purified by Sephadex LH-20 chromatography (CH2Cl2/MeOH 1:1) and 
RP-18 chromatography (10 mM AcOH-Et3N (pH 7.0)/MeOH 90:10→0:100) to give N-
benzyloxycarbonyl-2-aminoethyl O-(3,4-di-O-benzyl-2-deoxy-2-sulfamido-6-O-sulfo-
α-D-glucopyranosyl)-(1→4)-O-(3-O-benzyl-2-O-sulfo-α-L-idopyranosyluronic acid)-
(1→4)-O-(3-O-benzyl-2-deoxy-2-sulfamido-6-O-sulfo-α-D-glucopyranosyl)-(1→4)-3-
O-benzyl-2-O-sulfo-α-L-idopyranosiduronic acid as triethylammonium salt. The 
corresponding sodium salt was obtained by elution from a column of Dowex 50WX4-
Na+ with MeOH/H2O 9:1. TLC (EtOAc-Py-H2O-AcOH 5:5:3:1) Rf 0.57;
 1H-NMR (500 
MHz, MeOD): δ 7.52-7.05 (m, 30H, Ar), 5.99 (bs, 1H, H-1C), 5.36 (d, 1H, J1,2 = 3.6 
Hz, H-1D), 5.32-5.26 (m, 4H, H-1A (5.32), H-1B (5.30), CH2(OBn)), 5.03 (m, 2H, 
CH2(Z)), 4.93 (d, 1H, CH2(OBn)), 4.80 (bs, 1H, H-5C), 4.77-4.71 (m, 6H, H-2A (4.74), 
H-2C (4.73), CH2(OBn)), 4.68 (d, 1H, CH2(OBn)), 4.61 (bs, 1H, H-5A), 4.57 (d, 1H, 
CH2(OBn)), 4.51-4.47 (m, 2H, H-3A (4.50), CH2(OBn)), 4.41 (m, 1H, H-5B), 4.37-4.32 
(m, 3H, H-3C (4.36), H-6aD, H-6bD), 4.20-4.06 (m, 6H, H-4C (4.18), H-6aB (4.16), H-
4A (4.13), H-6bB (4.11), H-5D (4.09), H-3B (4.08)), 3.88 (t, 1H, J3,4 = J4,5 = 10.4 Hz, 
H-4B), 3.85 (t, 1H, J2,3 = J3,4 = 9.8 Hz, H-3D), 3.73 (m, 1H, CH2-O), 3.62-3.50 (m, 4H, 
H-4D (3.60), H-2B (3.56), H-2D (3.53), CH2-O), 3.31 (m, 2H, CH2-N);
 13C-NMR (125 
MHz, MeOD) (Significant data from HSQC experiment): δ 100.1 (C-1D), 100.0 
(C-1A), 97.2 (C-1B), 94.4 (C-1C), 81.4 (C-3D), 78.8 (C-4D), 77.1 (C-4B), 76.4 (C-4C), 
76.2, 76.0 (CH2(OBn)), 75.9 (C-3B), 75.5 (C-3C), 75.2 (CH2(OBn)), 74.6 (C-4A), 72.9 
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(C-2A), 72.8, 72.6 (CH2(OBn)), 71.7 (C-3A), 71.5 (C-2C), 70.8 (C-5D), 69.6 (C-5C), 
68.8 (C-5A), 68.6 (C-5B), 68.4 (C-6B), 68.0 (CH2-O), 67.6 (C-6D), 67.3 (CH2(Z)), 60.2 
(C-2B), 59.7 (C-2D), 41.3 (CH2-N); ESI MS: m/z: calcd for C69H73N3O41S6Na6: 964.5; 
found: 964.5 [M+6Na]2-; calcd for C69H73N3O41S6Na10: 1010.6; found: 1010.6 
[M+10Na]2+. 
A solution of this compound (5 µmol, as sodium salt) in H2O/MeOH (2.7 
mL/0.3 mL) was hydrogenated in the presence of Pd(OH)2. After 24 h, the suspension 
was filtered over Celite and concentrated. The residue was purified by Sephadex G-25 
chromatography (H2O/MeOH 9:1) to give 22 after lyophilisation (3.2 mg, 47% from the 
O-sulfated intermediate, 3 steps; 36% from 19, 5 steps, 82% average yield per step). 1H-
NMR (500 MHz, D2O): δ 5.47 (d, 1H, J1,2 = 3.6 Hz, H-1B), 5.39 (d, 1H, J1,2 = 3.5 Hz, 
H-1D), 5.21 (bd, 1H, H-1C), 5.08 (d, 1H, J1,2 = 4.1 Hz, H-1A), 4.82 (bd, 1H, H-5C), 
4.53 (d, 1H, J4,5 = 3.2 Hz, H-5A), 4.40-4.25 (m, 5H, H-2C (4.34), H-2A (4.31), H-6aB, 
H-6aD, H-6bB or H-6bD), 4.21-4.16 (m, 3H, H-3C, H-3A, H-6bB or H-6bD), 4.14 (t, 
1H, J3,4 = J4,5 = 3.8 Hz, H-4A), 4.08 (bt, 1H, H-4C), 4.05-3.97 (m, 3H, H-5B, H-5D, 
CH2-O), 3.81 (m, 1H, CH2-O), 3.76 (t, 1H, J3,4 = J4,5 = 9.5 Hz, H-4B), 3.67-3.61 (m, 2H, 
H-3B, H-3D), 3.56 (t, 1H, J3,4 = J4,5 = 9.6 Hz, H-4D), 3.29-3.21 (m, 4H, H-2B, H-2D, 
CH2-N);
 13C-NMR (125 MHz, D2O) (Significant data from HSQC experiment): δ 99.6 
(C-1A), 99.1 (C-1C), 97.2 (C-1D), 95.9 (C-1B), 77.5 (C-2A), 76.1 (C-4B, C-4C), 75.9 
(C-4A), 75.4 (C-2C), 69.9 (C-5A, C-3A, C-5D), 69.3 (C-3B, C-3D), 69.1 (C-5B, C-4D), 
68.9 (C-5C), 68.5 (C-3C), 66.5, 66.3 (C-6B, C-6D), 64.4 (CH2-O), 58.0 (C-2B), 57.8 
(C-2D), 39.4 (CH2-N); ESI MS: m/z: calcd for C26H38N3O39S6Na5: 661.45; found: 
661.44 [M+5Na+H]2-; calcd for C26H39N3O39S6Na4: 650.46; found: 650.45 
[M+4Na+2H]2-; calcd for C26H40N3O39S6Na3: 639.47; found: 639.46 [M+3Na+3H]
2-. 
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2-aminoethyl O-(2-deoxy-2-sulfamido-4,6-di-O-sulfo-α-D-glucopyranosyl)-(1→4)-
O-(2-O-sulfo-α-L-idopyranosyluronic acid)-(1→4)-O-(2-deoxy-2-sulfamido-6-O-
sulfo-α-D-glucopyranosyl)-(1→4)-O-(2-O-sulfo-α-L-idopyranosyluronic acid)-
(1→4)-O-(2-deoxy-2-sulfamido-6-O-sulfo-α-D-glucopyranosyl)-(1→4)-2-O-sulfo-α-
L-idopyranosiduronic acid (23): H2O2 (30%, 1.4 mL) and a solution of LiOH (0.7 M, 
0.84 mL) were added at -5ºC to a solution of 14 (76 mg, 34 µmol) in THF (3.8 mL). 
After stirring for 20 h at room temperature, MeOH (3.8 mL) and a solution of NaOH (4 
M, 0.87 mL) were added. After stirring for 20-24 h at room temperature, the reaction 
mixture was neutralized with a 4 M solution of HCl and then diluted with CH2Cl2 (80 
mL) and washed with H2O (40 mL). The organic phase was extracted with a solution of 
Na2SO3 (10%), dried (MgSO4), filtered, and concentrated to give the desired saponified 
hexasaccharide (60 mg, 97%). ESI MS: m/z: calcd for C88H96N10O33Na3: 1889.6; found: 
1889.5 [M+3Na-4H]-; calcd for C88H99N10O33: 1823.6; found: 1823.5 [M-H]
+. 
This compound (12 mg, 6.7 µmol) and sulfur trioxide–trimethylamine complex 
(33 mg, 230 µmol) were dissolved in dry DMF (1.0 mL) and heated for 30 min at 100ºC 
using microwaves as described above. The reaction vessel was cooled and Et3N (150 
µL), MeOH (1 mL) and CH2Cl2 (1 mL) were added. The solution was layered on the 
top of a Sephadex LH-20 chromatography column which was eluted with 
CH2Cl2/MeOH (1:1) to obtain the desired hepta O-sulfated hexasaccharide as 
triethylammonium salt. The corresponding sodium salt was obtained by elution from a 
column of Dowex 50WX4-Na+ with MeOH/H2O 3:1. TLC (EtOAc-Py-H2O-AcOH 
5:5:3:1) Rf 0.42; 
1H-NMR (500 MHz, MeOD): δ 7.52-7.18 (m, 35H, Ar), 5.53 (bs, 1H, 
H-1E), 5.47 (bs, 1H, H-1C), 5.22 (bs, 1H, H-1A), 5.21 (d, 1H, CH2(OBn)), 5.12 (d, 1H, 
J1,2 = 3.7 Hz, H-1B or H-1D), 5.09 (d, 1H, J1,2 = 3.8 Hz, H-1B or H-1D), 5.07 (bs, 3H, 
H-1F, CH2(Z)), 5.04 (bs, 1H, H-5C), 5.03 (bs, 1H, H-5E), 4.90-4.79 (m, 3H, CH2(OBn), 
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H-5A (4.82)), 4.77-4.59 (m, 7H, CH2(OBn), H-2E (4.62)), 4.53 (bs, 2H, H-2C, H-2A), 
4.50 (m, 2H, CH2(OBn), H-6aF), 4.49-4.42 (m, 2H, CH2(OBn)), 4.36-4.15 (m, 11H, H-
4F, H-6aB, H-6aD, H-3E, H-3C, H-3A, H-6bB, H-6bD, H-6bF, H-4A, H-4C), 4.07 (m, 
2H, H-4B, H-4D), 4.03 (m, 1H, H-4E), 4.00 (m, 1H, H-5B or H-5D), 3.94 (m, 1H, H-
5F), 3.90-3.73 (m, 4H, H-3F, CH2-O, H-5B or H-5D, H-3B or H-3D), 3.71-3.60 (m, 2H, 
H-3B or H-3D, CH2-O), 3.45-3.39 (m, 2H, H-2F, H-2B or H-2D), 3.37 (m, 2H, CH2-N), 
3.31 (m, 1H, H-2B or H-2D); 13C-NMR (125 MHz, MeOD) (Significant data from 
HSQC experiment): δ 100.1 (C-1A), 98.6 (C-1E), 98.5 (C-1C), 96.8, 96.1 (C-1B, C-
1D), 95.8 (C-1F), 80.2 (C-3F), 80.1, 79.7 (C-3B, C-3D), 78.0 (C-4F), 76.7, 76.5, 76.1, 
73.5, 73.3 (CH2(OBn)), 72.9 (C-3A or C-3C), 72.7 (C-2A), 72.3 (C-4B, C-4D), 72.1 
(C-4A), 71.5 (C-4E, C-2C), 71.4 (C-3E, C-3A or C-3C), 71.3, 71.2 (C-5B, C-5D), 71.1 
(C-4C, C-5F), 70.9 (C-2E), 68.3 (CH2-O), 68.1 (C-5A), 67.8 (C-6F), 67.5 (C-5C, C-5E), 
67.4 (CH2(Z), C-6B, C-6D), 65.9, 65.3 (C-2B, C-2D), 64.5 (C-2F), 41.5 (CH2-N); ESI 
MS: m/z: calcd for C142H237N19O54S7: 1648.2; found: 1648.3 [M+9Et3NH+3H]
2+. 
This hexasaccharide (6.7 µmol) was dissolved in THF (2.4 mL) and treated with 
a 0.1 M aqueous solution of NaOH (0.96 mL). Then, a solution of Me3P in THF (88 µL 
of a 1 M solution) was added and the reaction was stirred for 6 h. The reaction mixture 
was neutralized with a 0.1 M solution of HCl and concentrated. MeOH (1 mL), CH2Cl2 
(1 mL) and Et3N (250 µL) were added, and the solution was layered on the top of a 
Sephadex LH-20 chromatography column which was eluted with CH2Cl2/MeOH (1:1) 
to obtain the corresponding intermediate. TLC (EtOAc-Py-H2O-AcOH 8:5:3:1) Rf 0.56; 
ESI MS: m/z: calcd for C88H97N4O54S7Na10: 2527.2; found: 2527.2 [M+10Na+H]
+; 
calcd for C88H97N4O54S7Na8:2481.2; found: 2481.0 [M+8Na+H]
-. 
This hexasaccharide (6.7 µmol) and sulfur trioxide–trimethylamine complex (31 
mg, 219 µmol) were dissolved in dry DMF (2.0 mL) in a 5 mL microwave reaction vial 
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under an argon atmosphere. Et3N (250 µL) was added and the reaction mixture was 
subjected to microwave radiation for 30 min at 60ºC (20 W average power). The 
reaction vessel was cooled under a stream of nitrogen. The reaction mixture was 
purified by Sephadex LH-20 chromatography (CH2Cl2/MeOH 1:1) and RP-18 
chromatography (10 mM AcOH-Et3N (pH 7.0)/Acetonitrile 95:5→50:50) to give the 
desired tri N-sulfated hexasaccharide as triethylammonium salt. The corresponding 
sodium salt was obtained by elution from a column of Dowex 50WX4-Na+ with 
MeOH/H2O 3:1. TLC (EtOAc-Py-H2O-AcOH 6:5:3:1) Rf 0.21; 
1H-NMR (500 MHz, 
MeOD): δ 7.59-7.06 (m, 35H, Ar), 6.05 (bs, 1H, H-1E), 6.01 (bs, 1H, H-1C), 5.35-5.30 
(m, 6H, H-1A, H-1B, H-1D, H-1F, CH2(OBn)), 5.05 (m, 2H, CH2(Z)), 4.96-4.80 (m, 
6H, H-5E (4.92), H-5C (4.81), CH2(OBn)), 4.77-4.42 (m, 14H, H-5A (4.69), H-2E 
(4.67), H-2C (4.64), H-2A (4.53), H-5B, H-5D, H-6aF (4.52), H-6bF (4.45), 
CH2(OBn)), 4.35-4.03 (m, 15H, H-4C (4.27), H-4E (4.24), H-4F (4.24), H-4A (4.20), 
H-3C (4.20), H-3A (4.13), H-3E (4.13), H-3B, H-3D, H-3F, H-5F (4.05), H-6aB, H-
6bB, H-6aD, H-6bD), 3.95 (t, 1H, H-4B or H-4D), 3.80 (m, 1H, CH2-O), 3.74 (t, 1H, H-
4B or H-4D), 3.61-3.52 (m, 4H, CH2-O, H-2B, H-2D, H-2F), 3.33 (m, 2H, CH2-N); 
13C-NMR (125 MHz, MeOD) (Significant data from HSQC experiment): δ 99.5 (C-1A), 
96.8 (C-1B, C-1D, C-1F), 94.3 (C-1C), 94.2 (C-1E), 77.6 (C-4B or C-4D), 77.4 (C-4F), 
77.1 (C-4B or C-4D), 75.4, 75.2, 74.9 (CH2(OBn)), 74.3 (C-3A, C-3E), 73.6-70.8 (C-
3C, C-3B, C-3D, C-3F, C-4A, C-4C (73.2), C-4E (71.8), C-2A (71.8), C-2C (72.4), 
C-2E (71.2), C-5B, C-5D, CH2(OBn)), 69.6 (C-5C), 69.4 (C-5F), 69.1 (C-5E), 68.7 (C-
5A), 68.1 (C-6B or C-6D), 67.9 (C-6F), 67.7 (C-6B or C-6D), 67.3 (CH2(Z)), 67.2 
(CH2-O), 60.1 (C-2B, C-2D, C-2F), 42.0 (CH2-N); ESI MS: m/z: calcd for 
C130H212N11O63S10Na: 1639.0; found: 1639.2 [M+7Et3NH+Na+7H]
2+; calcd for 
C142H243N13O63S10: 1729.2; found: 1729.7 [M+9Et3NH+6H]
2+. 
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A solution of this hexasaccharide (6.7 µmol, as sodium salt) in H2O/MeOH (1.8 
mL/0.2 mL) was hydrogenated in the presence of Pd(OH)2. After 24 h, the suspension 
was filtered over Celite and concentrated. The residue was purified by Sephadex G-25 
chromatography (H2O/MeOH 9:1) to give 23 after lyophilisation (4.4 mg, 31% from the 
saponified intermediate, 4 steps; 30% from 14, 5 steps, 79% average yield per step). 1H-
NMR (500 MHz, D2O): δ 5.50-5.47 (m, 2H, H-1F, H-1B or H-1D), 5.43 (d, 1H, J1,2 = 
3.4 Hz, H-1B or H-1D), 5.27-5.21 (m, 2H, H-1C, H-1E), 5.12 (d, 1H, J1,2 = 3.8 Hz, 
H-1A), 4.84 (m, 2H, H-5C, H-5E), 4.56 (d, 1H, J4,5 = 3.1 Hz, H-5A), 4.48-4.26 (m, 10H, 
H-2A, H-2C, H-2E, H-6aB, H-6aD, H-6aF, H-6bB, H-6bD, H-6bF, H-4F), 4.24-4.19 
(m, 3H, H-3A, H-3C, H-3E), 4.18-4.10 (m, 4H, H-4A, H-4C, H-4E, H-5F), 4.09-4.02 
(m, 3H, H-5B, H-5D, CH2-O), 3.87-3.76 (m, 4H, CH2-O, H-4B, H-4D, H-3F), 3.74-3.64 
(m, 2H, H-3B, H-3D), 3.36 (dd, 1H, J1,2 = 3.3 Hz, J2,3 = 10.8 Hz, H-2F), 3.33-3.21 (m, 
4H, H-2B, H-2D, CH2-N); 
13C-NMR (125 MHz, D2O) (Significant data from HSQC 
experiment): δ 99.6 (C-1A), 99.2 (C-1C, C-1E), 96.4 (C-1B or C-1D), 95.9 (C-1F, C-1B 
or C-1D), 77.1 (C-2A, C-4F), 75.9 (C-4B, C-4D, C-4A, C-4C, C-4E, C-2C, C-2E), 69.9 
(C-5A), 69.4 (C-3A, C-3C, C-3E, C-3B, C-3D, C-3F), 69.2 (C-5C, C-5E), 69.0 (C-5B, 
C-5D), 68.1 (C-5F), 66.4 (C-6B, C-6D, C-6F), 64.4 (CH2-O), 57.8 (C-2B, C-2D), 57.4 
(C-2F), 39.1 (CH2-N); ESI MS: m/z: calcd for C38H51N4O61S10Na10: 696.24; found: 
696.22 [M+10Na]3-.  
2-aminoethyl O-(2-deoxy-2-sulfamido-6-O-sulfo-α-D-glucopyranosyl)-(1→4)-O-(2-
O-sulfo-α-L-idopyranosyluronic acid)-(1→4)-O-(2-deoxy-2-sulfamido-6-O-sulfo-α-
D-glucopyranosyl)-(1→4)-O-(2-O-sulfo-α-L-idopyranosyluronic acid)-(1→4)-O-(2-
deoxy-2-sulfamido-6-O-sulfo-α-D-glucopyranosyl)-(1→4)-2-O-sulfo-α-L-
idopyranosiduronic acid (24): H2O2 (30%, 0.64 mL) and a solution of LiOH (0.7 M, 
0.38 mL) were added at -5ºC to a solution of 20 (36 mg, 15 µmol) in THF (1.7 mL). 
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After stirring for 20 h at room temperature, MeOH (1.7 mL) and a solution of NaOH (4 
M, 0.39 mL) were added. After stirring for 20-24 h at room temperature, the reaction 
mixture was neutralized with a 4 M solution of HCl and then diluted with CH2Cl2 (20 
mL) and washed with H2O (10 mL). The organic phase was extracted with a solution of 
Na2SO3 (10%), dried (MgSO4), and concentrated to give the desired saponified 
intermediate. ESI MS: m/z: calcd for C95H102N10O33Na3: 1979.6; found: 1979.5 
[M+3Na-4H]-. 
This compound (15 µmol) and sulfur trioxide–trimethylamine complex (64 mg, 
462 µmol) were dissolved in dry DMF (2.0 mL) and heated for 30 min at 100ºC using 
microwaves as described above. The reaction vessel was cooled and Et3N (150 µL), 
MeOH (1 mL) and CH2Cl2 (1 mL) were added. The solution was layered on the top of a 
Sephadex LH-20 chromatography column which was eluted with CH2Cl2/MeOH (1:1) 
to give the desired hexa O-sulfated hexasaccharide as triethylammonium salt. The 
corresponding sodium salt was obtained by elution from a column of Dowex 
50WX4-Na+ with MeOH/H2O 3:1 (30 mg, 75% from 20, 2 steps). TLC (EtOAc-Py-
H2O-AcOH 8:5:3:1) Rf 0.24;
 1H-NMR (500 MHz, MeOD): δ 7.42-7.16 (m, 40H, Ar), 
5.93 (bs, 1H, H-1E), 5.82 (bs, 1H, H-1C), 5.23-5.10 (m, 4H, H-1F (5.21), H-1B or H-
1D, H-1A (5.16), CH2(OBn)), 5.09-4.88 (m, 9H, H-1B or H-1D, CH2(Z), CH2(OBn)), 
4.84-4.50 (m, 13H, H-5E, H-5C, H-2E (4.70), H-2C (4.65), H-5A (4.61), H-2A (4.52), 
CH2(OBn)), 4.41-3.98 (m, 16H, H-3E (4.39), H-6aB, H-6aD, H-6aF, H-3C (4.33), 
H-6bB, H-6bD, H-6bF, H-3A (4.27), H-4C, H-4E (4.11), H-4A (4.09), H-4B, H-4D, 
H-5B, H-5D), 3.89 (m, 1H, H-3F), 3.81-3.46 (m, 9H, H-3B, H-3D, CH2-O, H-2F (3.65), 
H-5F (3.64), H-4F (3.63), H-2B, H-2D), 3.36 (m, 2H, CH2-N);
 13C-NMR (125 MHz, 
MeOD) (Significant data from HSQC experiment): δ 100.6 (C-1A), 95.4 (C-1C), 94.9 
(C-1E), 94.7, 93.8 (C-1B, C-1D), 93.7 (C-1F), 82.5 (C-3F), 79.4 (C-4F), 78.8, 78.7 
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(C-3B, C-3D), 76.0, 75.9, 75.6, 74.8 (CH2(OBn)), 72.6 (C-4A), 72.5, 72.4 (CH2(OBn)), 
71.3 (C-2C), 71.2 (C-2A), 71.1 (C-3A), 70.8-69.5 (C-4E, C-5F, C-2E, C-3E, C-3C, 
C-4C, C-4B, C-4D, C-5B, C-5D), 69.1 (C-5C, C-5E), 68.2 (C-5A), 67.6 (CH2-O), 67.2 
(CH2(Z), 66.7 (C-6B, C-6D, C-6F), 65.7 (C-2F), 65.2 (C-2B, C-2D), 41.3 (CH2-N); ESI 
MS: m/z: calcd for C95H97N10O51S6Na7: 1273.1; found: 1272.1 [M+7Na]
2-. 
This O-sulfated hexasaccharide (15 mg, 5.8 µmol) was dissolved in THF (2.0 
mL) and treated with a 0.1 M aqueous solution of NaOH (0.77 mL). Then, a solution of 
Me3P in THF (70 µL of a 1 M solution) was added and the reaction was stirred for 6 h. 
The reaction mixture was neutralized with a 0.1 M solution of HCl and concentrated to 
obtain the desired amino containing compound. TLC (EtOAc-Py-H2O-AcOH 10:5:3:1) 
Rf 0.34; ESI MS: m/z: calcd for C95H103N4O51S6Na8: 2491.3; found: 2491.1 [M+8Na]
-; 
calcd for C95H103N4O51S6Na7: 1234.2; found: 1234.0 [M+7Na]
2-. 
This compound (5.8 µmol) and sulfur trioxide–trimethylamine complex (25 mg, 
174 µmol) were dissolved in dry DMF (2.0 mL) in a 5 mL microwave reaction vial 
under an argon atmosphere. Et3N (200 µL) was added and the reaction mixture was 
subjected to microwave radiation for 30 min at 60ºC (20 W average power). The 
reaction vessel was cooled under a stream of nitrogen. The reaction mixture was 
purified by Sephadex LH-20 chromatography (CH2Cl2/MeOH 1:1) to afford the 
corresponding tri N-sulfated hexasaccharide as triethylammonium salt. The sodium salt 
was obtained by elution from a column of Dowex 50WX4-Na+ with MeOH/H2O 3:1. 
TLC (EtOAc-Py-H2O-AcOH 26:25:15:5) Rf 0.26. 
A solution of this compound (5.8 µmol, as sodium salt) in H2O/MeOH (1.35 
mL/0.15 mL) was hydrogenated in the presence of Pd(OH)2. After 24 h, the suspension 
was filtered over Celite and concentrated. The residue was purified by Sephadex G-25 
chromatography (H2O/MeOH 9:1) to give 24 after lyophilisation (2.0 mg, 17% from the 
 51 
O-sulfated intermediate, 3 steps; 13% from 20, 5 steps, 66% average yield per step). 1H-
NMR (500 MHz, D2O): δ 5.48 (bd, 1H, H-1B or H-1D), 5.44 (bd, 1H, H-1F), 5.39 (bs, 
1H, H-1B or H-1D), 5.34 (bs, 1H, H-1C or H-1E), 5.25 (bs, 1H, H-1C or H-1E), 5.11 
(bd, 1H, H-1A), 4.90-4.83 (m, 2H, H-5E, H-5C), 4.55 (bd, 1H, H-5A), 4.46-3.99 (m, 
19H, H-6aB, H-6aD, H-6aF, H-6bB, H-6bD, H-6bF, H-2E, H-2C, H-2A (4.32), H-3A, 
H-3C, H-3E, H-4A (4.15), H-4C, H-4E, H-5B, H-5D, CH2-O (4.03), H-5F (4.01)), 3.87-
3.77 (m, 3H, H-4B, H-4D, CH2-O (3.82)), 3.75-3.63 (m, 3H, H-3B, H-3D, H-3F (3.66)), 
3.58 (t, 1H, J3,4 = J4,5 = 9.6 Hz, H-4F), 3.33-3.18 (m, 5H, H-2B, H-2D, H-2F, CH2-N 
(3.24)); 13C-NMR (125 MHz, D2O) (Significant data from HSQC experiment): δ 99.5 
(C-1A), 99.2, 98.9 (C-1C, C-1E), 96.9 (C-1B or C-1D), 96.7 (C-1F), 95.9 (C-1B or C-
1D), 77.7 (C-2A), 76.1 (C-4B or C-4D), 75.9 (C-4B or C-4D, C-4A, C-4C, C-4E, C-2C 
or C-2E), 75.2 (C-2C or C-2E), 70.9 (C-3F), 69.9 (C-3A, C-5A), 69.7 (C-5F), 69.5 
(C-5C, C-5E, C-3B, C-3D), 69.2 (C-4F), 69.1 (C-5B, C-5D), 68.7, 68.5 (C-3C, C-3E), 
66.4, 66.3 (C-6B, C-6D, C-6F), 64.5 (CH2-O), 57.8 (C-2B, C-2D, C-2F), 39.3 (CH2-N). 
ESI MS: m/z: calcd for C38H52N4O58S9Na9: 662.26; found: 662.24 [M+9Na]
3-; calcd for 
C38H53N4O58S9Na8: 654.94; found: 654.92 [M+8Na+H]
3-; calcd for C38H54N4O58S9Na7: 
647.61; found: 647.59 [M+7Na+2H]3-.  
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